document incorporate reference document form kannual report stockholder fiscal year part ii end december proxy statement annual meeting iii stockholder hold april table content item business item property item legal proceeding item submission matter vote security holder ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service iv item exhibit financial statement schedule report form k signature deferral program amend restate deferred payment director compensation plan offer letter computation ratio earning fix charge page annual report stockholders code conduct list subsidiary power attorney certify resolution board directors certification ceo certification cfo certification ceo certification cfotable content item business merck co inc company global researchdriven pharmaceutical product company discover develop manufacture market broad range innovative product improve human animal health directly joint ventures company sell product primarily drug wholesaler retailer hospital clinic government agency manage health care provider health maintenance organization institution companys professional representative communicate effectiveness safety value product health care professional private practice group practice manage care organization january company announce plan establish medco health solutions inc medco health separate publiclytraded company august spinoff medco health effect way pro rata dividend company stockholder outstanding share common stock medco health base letter rule company receive internal revenue service receipt medco health share distribution taxfree federal income tax purpose cash receive lieu fractional share taxable product sale sale category company product follow million atherosclerosis hypertensionheart failure antiinflammatoryanalgesic osteoporosis respiratory vaccinesbiological antibacterialantifungal ophthalmological urology human immunodeficiency virus hiv total follow spinoff company prior period consolidate statement income cash flow relate discussion restate present result medco health separately discontinue operation result spinoff product sale reflect sale medco health thirdparty sale base net selling price company medco health prior year amount restate conform current year presentation present net rebate discount company product include therapeutic preventive agent generally sell prescription treatment human disorder atherosclerosis product zocor simvastatin largestselle hypertensionheart failure product significant cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate antiinflammatoryanalgesic include vioxx rofecoxib arcoxia etoricoxib agent specifically inhibit cox enzyme responsible pain inflammation coxibs osteoporosis product fosamax alendronate sodium treatment prevention osteoporosis respiratory product singulair montelukast sodium leukotriene receptor antagonist treatment asthma relief symptom seasonal allergic rhinitis vaccinesbiological mmr ii measles mumps rubella virus vaccine live varivax varicella virus vaccine live live virus vaccine prevention chickenpox recombivax hb hepatitis b vaccine recombinant largestselle antibacterialantifungal product include primaxin imipenem cilastatin sodium new product cancida caspofungin acetate invanz ertapenem sodium ophthalmological cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution table content trusopt dorzolamide hydrochloride ophthalmic solution largestselle urology product proscar finasteride treatment symptomatic benign prostate enlargement hiv product include crixivan indinavir sulfate stocrin efavirenz treatment human immunodeficiency viral infection adult primarily include maxalt rizatriptan benzoate treatment acute migraine headache adult propecia finasteride treatment male pattern hair loss nonpromoted product pharmaceutical animal health supply sale company joint venture revenue company relationship astrazeneca lp primarily relate sale nexium esomeprazole magnesium prilosec omeprazole january food drug administration fda approve cancidas companys oncedaily intravenous antifungal medicine treatment candidemia bloodstream infection follow candida infection intraabdominal abscess peritonitis infection line abdominal cavity pleural space infection infection lining lung january company announce fda approve singulair relief symptom seasonal allergic rhinitis adult child young year age march fda approve emend aprepitant member new class medicine combination anti vomit medicine help prevent acute delay nausea vomiting associate initial repeat course highly emetogenic cancer chemotherapy include highdose cisplatin march fda approve cozaar hypertension medicine indicate reduce risk stroke patient hypertension leave ventricular hypertrophy lvh new indication base landmark losartan intervention endpoint reduction hypertension study life life study cozaar mark time antihypertensive treatment regimen demonstrate reduction risk stroke versus antihypertensive treatment regiman hypertensive patient lvh life study black patient hypertension lvh low risk stroke atenolol cozaar april fda approve change prescribe information zocor include result landmark heart protection study zocor mg recommend diet start dose zocor people coronary heart disease diabete zocor mg cholesterollowere medication prove reduce risk heart attack stroke people heart disease diabete regardless cholesterol level acquisition february company announce agree acquire aton pharma inc privately hold biotechnology company focus development novel treatment cancer disease january company wholly own subsidiary msd japan co ltd launch tender offer acquire estimate aggregate purchase price billion remain common share banyu pharmaceutical co ltd banyu october company announce close final count share second tender offer remain share banyu company own outstanding share banyu common stock japan world second large pharmaceutical market july company acquire rosetta inpharmatics inc publiclyheld washington base informational genomics company design develop unique technology efficiently analyze gene datum predict medical compound interact different kind cell body joint venture company enter agreement astra ab astra develop market astra product united states company astra form equally own joint venture develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach line company astra restructure joint venture company acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical lp partnership company maintain limited partner interest partnership rename astrazeneca lp exclusive distributor product table content kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent company share undistribute partnership gaap earning conjunction restructure payment million astra purchase option buy company interest kbi product exclude company interest gastrointestinal medicine nexium prilosec company grant astra option share option buy company common stock interest kbi exercise price base net present value estimate future net sale nexium prilosec april astra merged zeneca group plc form astrazeneca ab astrazeneca result merger exchange company relinquishment right future astra product exist pende patent time merger astra pay million subject trueup calculation require repayment portion merger trigger partial redemption company limited partner interest furthermore result merger astrazenecas option buy company interest kbi product exercisable company right require astrazeneca purchase interest addition share option exercisable year astra purchase company interest kbi product company form joint venture johnson johnson develop market manufacture consumer health care product united states own joint venture expand europe canada european extension currently market sell overthecounter pharmaceutical product france germany italy spain united kingdom significant joint venture product pepcid ac famotidine overthecounter form company ulcer medication pepcid famotidine pepcid complete overthecounter product combine company ulcer medication antacid calcium carbonate magnesium hydroxide february company announce intention sell johnson johnson interest european joint venture discuss divestiture effective april company merck vaccine division connaught laboratories inc aventis pasteur agree collaborate development marketing combination pediatric vaccine promote select vaccine united states research marketing collaboration enable company pool resource expedite development vaccine combine different antigen protect child variety disease include haemophilus influenzae type b hepatitis b diphtheria tetanus pertussis poliomyelitis combination vaccine development effort continue agreement vaccine currently promote company merck vaccine division pasteur mrieux connaught aventis pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution exist european union eu european free trade association company aventis pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc aventis pasteur msd snc joint venture subject monitor eu partner certain undertaking return exemption european competition law effective december joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden united kingdom distributor rest europe company rhnepoulenc sa combined respective animal health poultry genetic business form merial limited merial fullyintegrated animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal species december rhne poulenc sas interest merial acquire aventis sa corporation form merger rhnepoulenc sa hoechst ag table content company scheringplough corporation scheringplough enter agreement create separate equally own partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area december company scheringplough announce worldwide expansion exclude japan cholesterolmanagement partnership october merckscheringplough pharmaceuticals msp announce fda approval zetia ezetimibe oncedaily tablet zetia mg approve use statin reduce ldl cholesterol total cholesterol patient high cholesterol marketing approval receive october germany brand ezetrol use market statin treatment elevate cholesterol level follow successful completion european union mutual recognition procedure mrp ezetrol launch european country germany united kingdom switzerland sweden netherlands completion mrp process eu member states iceland norway grant national marketing authorization unify labeling ezetrol eu ezetrol indicate coadministration statin adjunctive therapy diet use patient primary hypercholesterolemia appropriately control statin ezetrol monotherapy indicate adjunctive therapy diet use patient primary hypercholesterolemia statin consider inappropriate tolerate addition ezetrol monotherapy indicate adjunctive therapy diet use patient homozygous familial sitosterolemia coadministere statin use patient homozygous familial hypercholesterolemia september msp submit fda standard review new drug application nda vytorin investigational cholesterol lower medicine contain active ingredient zetia zocor adjunctive diet reduction hypercholesterolemia elevate cholesterol level november filing accept fda standard review similar application file country outside united states competition market company pharmaceutical business conduct highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access competition involve intensive search technological innovation ability market innovation effectively long stand emphasis research development company prepare compete search technological innovation additional resource meet competition include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product joint venture license refine sale marketing effort address change industry condition enhance product portfolio company continue pursue external alliance earlystage latestage product opportunity include joint venture target acquisition introduction new product process competitor result price reduction product replacement product protect patent example number compound available treat disease typically increase time result slow growth sale certain company product addition particularly area human pharmaceutical product legislation enact state allow encourages instance absence specific instruction prescribe physician mandate use generic product contain active chemical innovator product brandname product governmental pressure dispense generic product significantly reduce sale certain company product long protect patent vasotec vaseretic enalapril maleate combination hydrochlorothiazide right sell prinivil lisinopril prinzide lisinopril combination hydrochlorothiazide pepcid mevacor lovastatin slow growth certain product distribution company sell human health product primarily drug wholesaler retailer hospital clinic government agency manage health care provider health maintenance organization institution vaccine sell directly physician companys professional representative table content communicate effectiveness safety value company product health care professional private practice group practice manage care organization fourth quarter company implement new distribution program wholesaler moderate fluctuation sale cause wholesaler investment buying improve efficiency distribution company pharmaceutical product new program lower previous limit average monthly purchase company pharmaceutical product customer overall implementation new wholesaler distribution program estimate million unfavorable impact consolidate revenue estimate million unfavorable effect zocor sale raw material raw material supply normally available quantity adequate meet need company business government regulation investigation pharmaceutical industry subject global regulation regional country state local agency particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states food drug administration modernization act pass culmination comprehensive legislative reform effort design streamline regulatory procedure fda improve regulation drug medical device food legislation principally design ensure timely availability safe effective drug biologic expedite premarket review process new product key provision legislation reauthorization prescription drug user fee act permit continue collection user fee prescription drug manufacturer augment fda resource earmark review human drug application help provide resource necessary ensure prompt approval safe effective new drug united states government significant progress expand health care access enact medicare prescription drug improvement modernization act sign law december statute add prescription drug coverage medicare begin voluntary drug discount card medicare beneficiary effective june implementation new benefit support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time benefit design assure prescription drug cost control competitive pressure encourage appropriate use medicine company take leadership role contribute success new medicareendorsed discount card offer provide medicine free lowincome medicare beneficiary exhaust transitional assistance allowance medicareendorse drug discount card action consistent company longstande patient assistance program provide free medicine patient unite states lack drug coverage afford medicine address cost containment outside medicare company continue effort demonstrate medicine help save cost overall patient health care addition pricing flexibility company product portfolio encourage grow use medicine mitigate effect increase cost pressure year pharmaceutical industry federal state oversight approval process new drug drug safety advertising promotion drug purchasing reimbursement program formulary variously review company believe continue able conduct operation include introduction new drug market regulatory environment type federal initiative contain federal health care spending prospective capitate payment system implement reduce rate growth medicare reimbursement hospital system establish advance flat rate reimbursement health care patient payer fiscally responsible type payment system cost containment system widely public private payer cause hospital health maintenance organization customer company costconscious table content treatment decision include decision medicine available patient company continue work private federal employer slow increase health care cost company effort demonstrate medicine help save cost area price flexibility product portfolio encourage use company medicine helped offset effect increase cost pressure federal state government pursue method directly reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion provide minimum discount define nonfederal average manufacturer price purchase certain component federal government department veterans affairs department defense initiative state seek rebate minimum require medicaid legislation case patient eligible medicaid federal vaccine child entitlement program center disease control prevention cdc fund purchase recommend pediatric vaccine public sector price immunization medicaideligible uninsured native american certain underinsured child company award cdc contract supply million pediatric vaccine program monovalent component certain vaccine outside united states company encounter similar regulatory legislative issue country business primary thrust governmental inquiry action determine drug safety effectiveness mechanism control price prescription drug profit prescription drug company eu adopt directive concern classification label advertise wholesale distribution approval marketing medicinal product human use company policy procedure consistent substance directive consequently believe material effect company business company subject jurisdiction regulatory agency subject potential administrative action action include seizure product civil criminal sanction certain circumstance company deem advisable initiate product recall company believe able compete effectively environment addition certain country eu recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative european commission proposal complete single market pharmaceutical improve competitive climate variety mean include market deregulation increase focus privacy issue country world include united states eu united states federal state government pursue legislative regulatory initiative patient privacy include federal recently issue state privacy regulation concern health information affect company operation patent trademarks license patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product se pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance date grant legal life patent country protection afford vary country country depend type patent scope coverage patent portfolio develop product introduce company normally provide market exclusivity basic patent effect follow major product united states arcoxia cancidas comvax haemophilus b conjugate hepatitis b recombinant vaccine cosopt cozaar crixivan emend fosamax table content hyzaar invanz maxalt pedvaxhib haemophilus b conjugate vaccine primaxin propecia proscar recombivax hb singulair timopticxe timolol maleate ophthalmic gel forming solution trusopt vioxx zocor basic patent effect united states zetia develop merckscheringplough pharmaceutical partnership basic patent effect sustivastocrin efavirenz bristolmyers squibb exclusive license company sell sustiva united states canada certain european country company market stocrin country world basic patent aggrastat tirofiban hydrochloride united states divest product company retain basic patent aggrastat outside united states zocor lose basic patent protection canada certain country europe include united kingdom germany company experience decline zocor sale country zocor lose market exclusivity united states company expect decline zocor sale fda modernization act modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant exclusivity provision reauthorize october good pharmaceuticals child act pass january fda grant additional month market exclusivity united states fosamax february fosamax weekly january addition fda grant additional month market exclusivity united states trusopt october vioxx month patent termination expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product ii patent relate use product iii patent relate novel composition formulation iv united states market exclusivity available federal law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset general increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty receive patent knowhow license right amount million company pay royalty amount million patent knowhow license hold divestiture february company announce sign definitive agreement johnson johnson johnson johnson buy company percent equity stake european nonprescription pharmaceutical joint venture company sell right aggrastat tirofiban hydrochloride injection guilford pharmaceuticals inc guilford include basic product patent process patent product table content company sell right vasotec vaseretic vasotec iv injection enalaprilat biovail laboratory incorporate biovail subsidiary biovail corporation time company canadian subsidiary merck frosst canada co merck frosst biovail enter supply agreement merck frosst agree supply biovail minimum year bulk tablet formulate enalapril maleate enalapril maleate combination hydrochlorothiazide distribution biovail united states vasotec vaseretic basic product patent vasotec vaseretic expire united states prior transaction research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity expenditure company research development program billion billion billion estimate increase lowteen percentage growth rate fullyear expense company maintain ongoing commitment research broad range therapeutic area clinical development support new product total expenditure period exceed billion compound annual growth rate company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development project relate human health carry field bacterial fungal viral infection cardiovascular disease atherosclerosis cancer diabetes obesity neurodegenerative disease psychiatric disease pain inflammation immunology respiratory disease ophthalmology respiratory disease osteoporosis menwomen health program endoparasitic ectoparasitic disease companion animal disease production improvement development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug market united states record datum preclinical clinical experience include nda biological product license application pla fda require approval development certain product subject government regulation cover safety efficacy united states foreign country assurance compound result particular program obtain regulatory approval necessary market company latestage pipeline candidate include novel vaccine human papillomavirus hpv pain associate shingles rotateq vaccine rotavirusa highly contagious virus common cause severe gastroenteritis infant young child company expect file pla fda novel vaccine candidate second half compete claim intellectual property hpv field company confident claim delay company program company expect submit pla fda proquad vaccine pediatric combination vaccine measle mump rubella chickenpox second half company study dpiv inhibitor glucoselowering mechanism combination treatment type ii diabetes company plan enter phase iii clinical trial investigational compound second quarter expect submit nda fda company earlystage pipeline include candidate follow area diabetes obesity alzheimer disease respiratory disease coronary heart disease rheumatoid arthritis vaccine company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology company complete significant transaction include research collaboration preclinical clinical compound technology transaction transaction complete include agreement table content follow company genpath cancer amrad respiratory disease neurogen pain actelion cardiovascular disease february company announce enter agreement h lundbeck lundbeck develop commercialize united states gaboxadol compound license lundbeck party currently phase iii development treatment sleep disorder term agreement lundbeck receive initial payment million million additional milestone payment company lundbeck jointly complete ongoing phase iii clinical program company fund majority remain development activity company anticipate file nda fda late mid follow fda approval company plan copromote gaboxadol united states lundbeck receive share gaboxadol sales united states february company announce agree acquire aton pharma inc aton privately hold biotechnology company focus development novel treatment cancer disease consideration acquisition consist upfront contingent payment base regulatory filing approval sale product aton clinical pipeline histone deacetylase inhibitor represent class antitumor agents potential efficacy base novel mechanism action aton lead product candidate know suberoylanilide hydroxamic acid extensively study phase clinical trial currently phase ii clinical trial treatment cutaneous tcell lymphoma company expect complete acquisition aton quarter chart reflect company research pipeline march candidate show phase iii include specific product candidate show phase ii include advanced compound specific mechanism give therapeutic area backup compound regardless phase development additional indication therapeutic area additional line extension formulation inline product show preclinical area show company initiate good laboratory practice glp study compound mechanism distinct phase ii company program generally design focus development novel medicine address large unmet medical need table content preclinical phase phase ii phase iii diabetes diabete c obesity vaccine atherosclerosis obesity c pediatric combination c alzheimer disease vaccine parkinson disease c c proquad atherosclerosis urinary incontinence rotavirus pain c c rotateq alzheimer disease respiratory disease shingle anxiety c c zoster vaccine c postoperative nausea human papillomavirus osteoporosis multiple sclerosis vomit hpv vaccine c c cancer pain vaccine diabete c pediatric combination mk q rheumatoid arthritis psychiatric disease c sleep disorder glaucoma respiratory disease mk gaboxadol c antibacterial rheumatoid arthritis c vaccines c aids c vaccines hiv vaccine submission cardiovascular arthritis analgesia vytorin arcoxia ezetimibe simvastatin submit q submit q february company announce discontinued phase ii clinical trial lead gabaa agonist compound treatment generalize anxiety company continue research field anxiety ongoing study gaba agonist molecules time development molecule certain april company announce discontinuing development lead phosphodiesterase pde inhibitor compound phase ii clinical trial treatment asthma chronic obstructive pulmonary disease copd company continue research field asthma copd ongoing study pde inhibitor molecule time development molecule certain august company announce phase clinical trial lead hiv integrase inhibitor compound hold company continue research field integrase inhibitor ongoing study integrase inhibitor time development molecule certain november company announce discontinuing phase iii clinical development program substance p antagonist investigational product mk treatment depression phase iii clinical program halt compound fail demonstrate efficacy treatment depression company remain committed neuroscience research program november company announce discontinuing phase iii clinical development program investigational product mk treatment diabetes company table content develop mk collaboration kyorin pharmaceutical co ltd clinical program halt recent finding company longterm safety assessment program identify rare form malignant tumor mice clinical relevance finding human unknown company continue commitment diabetes research currently study dpiv inhibitor diabete company plan enter phase iii clinical trial investigational compound second quarter february banyu announce change time respect file japan nda rofecoxib vioxx press release banyu state review clinical datum accumulate date recommendation organization pharmaceutical safety research banyu agree conduct additional study japanese patient support nda filing result decision nda filing originally plan place end march delay banyu state conduct additional study appropriate support filing product december company submit nda fda arcoxia company nda seek indication arcoxia treatment osteoarthritis rheumatoid arthritis chronic low pain acute pain dysmenorrhea acute gouty arthritis ankylose spondylitis painful condition spine january arcoxia launch country worldwide europe latin america asia pacific region fda inform company fda consider january effective submission date nda fiscal year fee different medicine receive december fda inform company company notify nda accept filing march november european unions committee proprietary medicinal product conclude comprehensive review cox selective inhibitor class include vioxx arcoxia confirm medicine positive balance benefit risk french transparency commission responsibility include recommend drug reimbursement level france review retain assessment vioxx provide modest level improvement relative nonsteroidal antiinflammatory drug term safety product service mark appear type form different surround text trademark service mark own license merck co inc subsidiarie affiliate include zetia trademark own entity merckscheringplough pharmaceutical partnership note cozaar hyzaar register trademark ei du pont de nemours company wilmington de prilosec nexium trademark astrazeneca group trademark vasotec vaseretic own biovail laboratory incorporate trademark aggrastat own guilford pharmaceuticals inc employee end company employee worldwide employ united states include puerto rico approximately worldwide employee company represent collective bargaining group company accelerate effort fundamentally low cost structure companywide initiative october company announce reduction position expect complete complete cost reduction expect generate annual saving payroll benefit cost million start environmental matter company believe compliance material respect applicable environmental law regulation company incur capital expenditure approximately million environmental protection facility company remediate environmental contamination result past industrial activity certain site expenditures remediation environmental liability table content million estimated million year amount consider potential recovery insurer party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess provide result material adverse effect company financial position result operation liquidity capital resource cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement subject risk uncertaintie identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially possible predict identify factor include follow generic competition product patent product recently expire united states country include product patent mevacor prinivil prinzide vaseretic zocor lose basic patent protection canada certain country europe include united kingdom germany company experience decline zocor sale country zocor lose market exclusivity united states company expect decline zocor sale addition patent cover omeprazole active ingredient prilosec company supply exclusively astrazeneca lp expire trial court hold october generic company omeprazole product infringe company formulation patent respect prilosec agreement astrazeneca company receive supply payment predetermine rate sale certain product astrazeneca notably prilosec nexium increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general company previously announce fourth quarter take action low cost structure include elimination position action continue change government law regulation enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale table content legal factor include product liability claim antitrust litigation governmental investigation environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states eu united states federal state government pursue legislative regulatory initiative patient privacy include federal recently issue state privacy regulation concern health information affect company operation change tax law include change relate taxation foreign earning impact legislation cap ultimately repeal section internal revenue code relate earning company puerto rican operation change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board securities exchange commission adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertaintie geographic area segment information company operation principally manage product basis reportable segment merck pharmaceutical segment include product market directly joint venture merck pharmaceutical product consist therapeutic preventive agent sell prescription treatment prevention human disorder company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale respectively company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition recent year company expand operation country locate latin america middle east africa eastern europe asia pacific change government policy economic condition make possible company earn fair return business develop area stable offer important opportunity growth time financial information geographic area operate segment company business incorporate reference page begin caption segment reporting company annual report stockholder available information company internet website address wwwmerckcom company available free charge investor information portion website annual report quarterly report form q current report form k amendment report file furnish pursuant section table content security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission company corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutcorporategovernance information available print stockholder request company item property companys corporate headquarters locate whitehouse station new jersey companys pharmaceutical business conduct divisional headquarters locate upper gwynedd west point pennsylvania principal research facility human health product locate rahway new jersey west point company production facility human health product location united states puerto rico branch warehouse provide service country outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia capital expenditure million compare million united state amount million million abroad expenditure amount million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action begin company name number antitrust suit certain certify class action institute nation retail pharmacy consumer state allege antitrust violation action pende state court consolidate pretrial purpose federal court chicago illinois company defendant settle federal class action represent single large group claim time company settle substantially remain case satisfactory term company engage conspiracy admission wrongdoing include settlement agreement feasible predict final outcome remain case opinion company proceeding ultimately result liability material adverse effect company financial position result operation liquidity previously disclose company advise department justice investigate marketing selling activity company pharmaceutical manufacturer connection investigation previously disclose government serve subpoena company production document relate company marketing sale activity subpoena seek substantially information government previously seek company work government respond appropriately subpoena informational request company receive civil investigative demand cid attorney general texas cid seek production document information company marketing selling activity relate texas company working texas attorney general office respond appropriately cid previously disclose company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level judicial panel multidistrict litigation table content order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like company defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissal plaintiff file amend consolidated class action complaint company defendant company thirty pharmaceutical manufacturer remain defendant similar complaint pende federal court massachusetts file new york county suffolk rockland westchester company believe lawsuit merit vigorously defend previously disclose january department justice notify federal court new orleans louisiana go intervene pende federal false claim act case file seal december company court issue order unseal complaint file physician louisiana ordered complaint serve complaint allege company discount pepcid certain louisiana hospital lead increase cost medicaid company believe complaint merit vigorously defend federal state lawsuit involve numerous individual claim putative class action file company respect vioxx lawsuit defendant pfizer inc market compete product certain lawsuit include allegation gastrointestinal bleed cardiovascular event kidney damage lawsuit file federal court number state court case jurisdiction proceed separately action file state court california new jersey transfer single judge state coordinate proceeding company anticipate lawsuit jurisdiction trial half litigation inherently subject uncertainty assurance give outcome give trial company believe lawsuit merit vigorously defend number purport class action lawsuit file individual shareholder united states district court eastern district louisiana naming defendant company current officer company allege defendant false misleading statement company drug vioxx violation federal security law plaintiff request certification class purchaser company common stock october seek unspecified compensatory damage cost suit include attorney fee company believe lawsuit merit vigorously defend company party claim bring consumer protection act united kingdom allege certain child suffer variety condition result vaccinate bivalent vaccine measle rubella andor trivalent vaccine measle mumps rubella include company mmr ii pharmaceutical company sue claimant allege adverse consequence include autism inflammatory bowel disease epilepsy diabete encephalitis encephalopathy chronic fatigue syndrome connection claim lead case select trial schedule commence april company pharmaceutical company trial case initially limit issue causation defect condition autistic spectrum disorder inflammatory bowel disease early september legal service commission announce decision withdraw public funding litigation bring claimant decision confirm appeal funding review committee september april trial date vacate claim stay pende outcome february hear judicial review funding withdrawal decision company believe lawsuit merit vigorously defend company party individual class action product liability lawsuit claim united states involve pediatric vaccine ie hepatitis b vaccine haemophilus influenza type b vaccine table content contain thimerosal preservative vaccine defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result thimerosal introduce develop body company successful case dismiss stay ground national vaccine injury compensation program nvicp prohibit person file maintain civil action seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim number similar case mmr ii andor thimerosalcontaining vaccine file united states court federal claim nvicp determination general causation issue company believe lawsuit claim merit vigorously defend proceeding party time time generic manufacturers pharmaceutical product file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax prilosec vioxx prior expiration company astrazenecas case prilosec patent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patent generic manufacturer receive fda approval market generic form prilosec company file patent infringement suit federal court company file andas generic alendronate rofecoxib astrazeneca company file patent infringement suit federal court company file andas generic omeprazole similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product trial united states respect alendronate daily product conclude november november decision issue district court delaware find company patent valid infringe october court appeal federal circuit affirm validity infringement company basic patent covering use alendronate form request rehear deny trial united states involve alendronate weekly product hold march august district court delaware uphold validity company patent cover weekly administration alendronate result court decision patent valid infringe teva pharmaceuticals usa incs teva abbreviate new drug application filing court decision appeal teva january high court justice england wale hold patent company protect alendronate daily weekly product invalid united kingdom november court appeal england wale affirm rule high court justice england wale protection generic company reference company datum weekly alendronate united kingdom available provision law grant period exclusivity original submitter datum generic company seek judicial review decision licensing authority united kingdom rely company weekly alendronate datum seek approval generic alendronate mg product year approval company weekly alendronate product grant company serve interested party intends appropriate action protect right case omeprazole trial court united states render opinion october uphold validity company astrazenecas patent cover stabilize formulation omeprazole rule defendant omeprazole product infringe patent defendant product find infringe formulation patent december court appeal federal circuit affirm decision trial court respect certain generic manufacturer omeprazole product trial date set table content case rofecoxib anda file include allegation noninfringement invalidity unenforceability company rofecoxib patent previously disclose company file patent infringement lawsuit district court delaware august trial set october previously disclose company name defendant number purport class action lawsuit consolidate single judge shareholder derivative action involve claim relate company revenue recognition practice retail copayment pay individual medco health provide pharmaceutical benefit class action lawsuit amend add claim company medco health certain officer director relate rebate receive medco health medco healths independent status shareholder derivative action amend add arthur andersen llp defendant add certain new allegation relate claim certain individual defendant breach fiduciary duty fail prevent conduct issue previously disclose gruer case discuss antitrust claim pende northern district illinois qui tam action attorney office eastern district pennsylvania intervene medco health complaint seek monetary damage company director defendant lawsuit unspecified injunctive relief spinoff medco health medco health assume responsibility portion potential damage settlement payment pay connection litigation company believe lawsuit merit vigorously defend prior spinoff medco health company medco health agree settle class action basis series lawsuit assert violation employee retirement income security act erisa company medco health certain plaintiff counsel file settlement agreement federal district court new york case commence number plaintiff include participant number pharmaceutical benefit plan medco health pharmacy benefit manager trustee plan consolidated propose class settlement agree plaintiff case gruer case file medco health company propose settlement company medco health agree pay total million medco health agree modify certain business practice continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december court preliminarily approve settlement hold hearing hear objection fairness propose settlement class member representative currently certain class member plan indicate participate settlement court approve settlement determine number class member plan properly elect participate settlement approve settlement final district court grant final approval appeal resolve medco health company agree propose settlement order avoid significant cost distraction protract litigation gruer case similar claim pende pharmaceutical benefit manager allege medco health erisa fiduciary company partyininterest mean erisa plaintiff assert company medco health breach duty engage prohibit transaction result fill prescription company drug increase company market share thing plaintiff demand medco health company disgorge unlawfully obtain profit relief addition case consolidate new york plaintiff allege base essentially factual allegation gruer case medco health company violate federal state racketeering law different plaintiff seek represent california citizens allege medco health company violate california unfair competition law attorney plaintiff indicate assert claim medco health company allege violation sherman act clayton act state antitrust law base allege conspiracy suppress price competition unlawful combination allegedly result high pharmaceutical price table content spinoff medco health medco health assume substantially liability exposure matter discuss forego paragraph company believe case defend medco health merit december virginia department environmental quality vadeq issue notice violation company elkton virginia facility air permit limit exceedance report facility result performance testing process train company currently discussion vadeq believe discussion result capital improvement monetary sanction immaterial exceed company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability de minimis cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost insurer site owner operator recalcitrant potentially responsible party legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company addition time time federal state regulator seek information practice pharmaceutical industry feasible predict outcome request information company expect inquiry material adverse effect financial position liquidity result operation company item submission matter vote security holder applicable table content executive officer registrant march raymond v gilmartin age june chairman board november president chief executive officer david w anstice age january president human health responsible company prescription drug business japan latin america canada australia new zealand company joint venture relationship scheringplough march president america human health responsible prescription drug division comprise human health company prescription drug business canada latin america company joint venture relationship scheringplough january president human healththe americas responsible company human health business united states canada latin america marcia j avedon age january senior vice president human resource september vice president talent management organization effectiveness prior september dr avedon hold senior human resource position honeywell international diversified manufacturing technology company richard clark age june president merck manufacturing division responsible company manufacture information service operational excellence organization worldwide january chairman president chief executive officer medco health solutions inc medco health whollyowne subsidiary company january president medco health june executive vice presidentchief operating officer medco health celia colbert age january vice president secretary september assistant general counsel november caroline dorsa age august vice president treasurer responsible company treasury tax function provide financial support merck manufacturing merck research laboratory division human resource september vice president treasurer responsible company treasury tax function provide financial support asia pacific division february vice president treasurer january responsible company treasury tax function table content kenneth c frazi age december senior vice president general counsel responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company january vice president deputy general counsel richard c henriques jr age august vice president controller responsible corporate controller group provide financial support human health operation united states canada latin america europe middle east africa japan australianew zealand merck vaccine division mvd november vice president controller responsible corporate controller group provide financial support human health canada latin america americas mvd february vice president controller january responsible corporate controller group provide financial support america peter kim age january president merck research laboratory mrl february executive vice president research development mrl prior february dr kim serve member whitehead institute professor biology massachusetts institute technology investigator howard hughes medical institute judy c lewent age january executive vice president chief financial officer president human health asia responsible financial corporate development function internal auditing corporate licensing company prescription drug business asia north asia south company joint venture relationship merck capital ventures llc subsidiary company february executive vice president chief financial officer responsible financial corporate development function internal auditing corporate licensing company joint venture relationship merck capital ventures llc november senior vice president chief financial officer responsible financial corporate development function internal auditing corporate licensing company joint venture relationship merck capital ventures llc january senior vice president january chief financial officer april responsible financial corporate development function internal auditing company joint venture relationship adel mahmoud age president merck vaccines november executive vice president merck vaccines table content margaret g mcglynn age january president human health responsible prescription drug division hospital specialty product franchise comprise human health ushh manage care group ushh august executive vice president customer marketing sale ushh november senior vice president worldwide human health marketing bradley sheare age january president human health responsible prescription drug division primary care product franchise comprise human health ushh march president human health responsible prescription drug division hospital specialty product franchise comprise ushh july vice president hospital marketing sale ushh joan e wainwright age january vice president public affairs june vice president corporate communication public affair prior june ms wainwright deputy commissioner communication social security administration woldolsen age january president human healtheurope middle east africa responsible company prescription drug business europe middle east africa worldwide human health marketing officer list serve pleasure board director officer elect pursuant arrangement understand officer board family relationship officer list table content ii item market registrant common equity relate stockholder matter issuer purchase equity security require information market information dividend incorporate reference company annual report stockholder require information number holder company common stock incorporate reference company annual report stockholder item select financial datum information require item incorporate reference datum fiscal year company include result year yearend position select financial datum table company annual report stockholder item management discussion analysis financial condition result operation information require item incorporate reference page company annual report stockholder item quantitative qualitative disclosure market risk information require item incorporate reference page begin caption analysis liquidity capital resource company annual report stockholder item financial statement supplementary datum financial statement consolidate balance sheet merck co inc subsidiary december relate consolidated statement income retain earning comprehensive income cash flow year period end december report date february pricewaterhousecooper llp independent auditor incorporate reference page respectively company annual report stockholder b supplementary datum select quarterly financial datum incorporate reference datum contain condense interim financial datum table company annual report stockholder item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule ae de securities exchange act amend effective significant change internal control financial reporting period cover report materially affect reasonably likely materially affect company internal control financial reporting table content iii item director executive officer registrant require information director nominee incorporate reference page company proxy statement annual meeting stockholder hold april information executive officer set forth document page require information audit committee financial expert incorporate reference head financial expert audit committee company proxy statement annual meeting stockholder hold april require information identification audit committee incorporate reference page caption board committee companys proxy statement annual meeting stockholder hold april require information compliance section security exchange act incorporate reference caption section beneficial ownership report compliance company proxy statement annual meeting stockholder hold april company adopt code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer code conduct available company website wwwmerckcomaboutcorporategovernance print stockholder request company intend post website amendment waivers code conduct item executive compensation information require item incorporate reference page caption compensation director caption compensation chief executive officer page begin caption annual benefit payable merck co inc retirement plans caption compensation committee interlock insider participation company proxy statement annual meeting stockholder hold april item security ownership certain beneficial owner management relate stockholder matter information respect security authorize issuance equity compensation plan incorporate reference page begin caption equity compensation plan information company proxy statement annual meeting stockholder hold april information respect security ownership certain beneficial owner management incorporate reference page caption security ownership certain beneficial owner management company proxy statement annual meeting stockholder hold april item certain relationship relate transaction information require item incorporate reference caption relationship outside firm caption indebtedness management company proxy statement annual meeting stockholder hold april item principal accountant fee service information require item incorporate reference page begin caption preapproval policy service independent auditor company proxy statement annual meeting stockholder hold april table content iv item exhibit financial statement schedule report form k document file financial statement follow consolidated financial statement report independent auditor incorporate reference company annual report stockholder note document consolidate statement income year end december consolidated statement retain earning year end december consolidate statement comprehensive income year end december consolidated balance sheet december consolidate statement cash flow year end december note consolidated financial statement report pricewaterhousecooper llp independent auditor financial statement schedule schedule omit require applicable financial statement affiliate carry equity basis omit consider individually aggregate affiliate constitute significant subsidiary exhibit exhibit number description master restructuring agreement date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june restate certificate incorporation merck co inc september incorporate reference form q quarterly report period end september bylaw merck co inc amend effective february incorporate reference form q quarterly report period end march executive incentive plan amend effective february incorporate reference annual report fiscal year end december management contract compensatory plan arrangement table content exhibit number description base salary deferral plan adopt october effective january incorporate reference form k annual report fiscal year end december merck co inc deferral program amend restate november incentive stock plan amend effective february incorporate reference annual report fiscal year end december incentive stock plan amend november incorporate reference form q quarterly report period end june incentive stock plan amend restate july incorporate reference form q quarterly report period end september incentive stock plan amend july incorporate reference registration statement form nonemployee director stock option plan amend restate february incorporate reference annual report fiscal year end december nonemployee director stock option plan amend april incorporate reference form q quarterly report period end june nonemployee directors stock option plan amend april incorporate reference form q quarterly report period end june supplemental retirement plan amend effective january incorporate reference annual report fiscal year end december retirement plan director merck co inc amend restate june incorporate reference form q quarterly report period end june plan defer payment director compensation amend restate november limited liability company agreement merck capital ventures llc date november incorporate reference annual report fiscal year end december offer letter merck co inc peter kim date december amend restate license option agreement date july astra ab astra merck inc incorporate reference form q quarterly report period end june management contract compensatory plan arrangement table content exhibit number description kbi share option agreement date july astra ab merck co inc merck holdings inc incorporate reference form q quarterly report period end june kbie asset option agreement date july astra ab merck co inc astra merck inc astra merck enterprises inc incorporate reference form q quarterly report period end june kbi supply agreement date july astra merck inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june second amend restate manufacturing agreement date july merck co inc astra ab astra merck inc astra usa inc incorporate reference form q quarterly report period end june limited partnership agreement date july kb usa lp kbi sub inc incorporate reference form q quarterly report period end june distribution agreement date july astra merck enterprises inc astra pharmaceutical lp incorporate reference form q quarterly report period end june agreement incorporate define term date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp incorporate reference form q quarterly report period end june computation ratio earning fix charge annual report stockholder portion incorporate reference document deem file code conduct value standard list subsidiary consent independent accountant contain report power attorney certify resolution board director rule ada certification chief executive officer rule ada certification chief financial officer section certification chief executive officer section certification chief financial officer table content instrument define right holder longterm debt company subsidiary exhibit number file total security authorize instrument take individually exceed total asset company subsidiary consolidate basis company agree furnish copy instruments commission request copy exhibit obtain stockholder write request direct stockholder service department merck co inc po box ws ab whitehouse station new jersey accompanied check payable merck co inc cover processing mailing cost b report form k threemonth period end december company furnish current report form k item regulation fd disclosure item result operation financial condition report date furnish october earning quarter certain supplemental information current report form k item regulation fd disclosure report date furnish december financial guidance ii report date furnish december annual business briefing presentation iii report date furnish december company annual business briefing analyst table content signature pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize merck co inc date march raymond v gilmartin chairman board president chief executive officer celia colbert celia colbert attorneyinfact pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date raymond v gilmartin chairman board march president chief executive officer principal executive officer director judy c lewent executive vice president chief march financial officer president human health asia principal financial officer richard c henriques jr vice president controller principal accounting officer march lawrence bossidy director march william g bowen director march johnnetta b cole director march william daley director march william b harrison jr director march william n kelley director march heidi g miller director march thomas e shenk director march samuel thi director march wendell p week director march peter c wendell director march celia colbert signing hereto sign document pursuant power attorney duly execute person name file security exchange commission exhibit document behalf person capacity date state person include majority director company celia colbert celia colbert attorneyinfact table content exhibit consent independent accountant consent incorporation reference registration statement form nos form nos merck co inc report date february relate consolidated financial statement appear annual report stockholder incorporate annual report pricewaterhousecooper llp florham park new jersey march table content exhibit index exhibit number description master restructuring agreement date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june restate certificate incorporation merck co inc september incorporate reference form q quarterly report period end september bylaw merck co inc amend effective february incorporate reference form q quarterly report period end march executive incentive plan amend effective february incorporate reference form k annual report fiscal year end december base salary deferral plan adopt october effective january incorporate reference annual report fiscal year end december merck co inc deferral program amend restate november incentive stock plan amend effective february incorporate reference annual report fiscal year end december incentive stock plan amend november incorporate reference form q quarterly report period end june incentive stock plan amend restate july incorporate reference form q quarterly report period end september incentive stock plan amend july incorporate reference registration statement form nonemployee director stock option plan amend restate february incorporate reference annual report fiscal year end december nonemployee director stock option plan amend april incorporate reference form q quarterly report period end june nonemployee directors stock option plan amend april incorporate reference form q quarterly report period end june supplemental retirement plan amend effective january incorporate reference annual report fiscal year end december management contract compensatory plan arrangement table content exhibit number description retirement plan director merck co inc amend restate june incorporate reference form q quarterly report period end june plan defer payment director compensation amend restate november limited liability company agreement merck capital ventures llc date november incorporate reference annual report fiscal year end december offer letter merck co inc peter kim date december amend restate license option agreement date july astra ab astra merck inc incorporate reference form q quarterly report period end june kbi share option agreement date july astra ab merck co inc merck holdings inc incorporate reference form q quarterly report period end june kbie asset option agreement date july astra ab merck co inc astra merck inc astra merck enterprises inc incorporate reference form q quarterly report period end june kbi supply agreement date july astra merck inc astra pharmaceutical lp portion exhibit subject request confidential treatment file commission incorporate reference form q quarterly report period end june second amend restate manufacturing agreement date july merck co inc astra ab astra merck inc astra usa inc incorporate reference form q quarterly report period end june limited partnership agreement date july kb usa lp kbi sub inc incorporate reference form q quarterly report period end june distribution agreement date july astra merck enterprises inc astra pharmaceutical lp incorporate reference form q quarterly report period end june agreement incorporate define term date june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical lp incorporate reference form q quarterly report period end june computation ratio earning fix charge annual report stockholder portion incorporate reference document deem file code conduct value standard management contract compensatory plan arrangement table content exhibit number description list subsidiary consent independent accountant contain report power attorney certify resolution board director rule ada certification chief executive officer rule ada certification chief financial officer section certification chief executive officer section certification chief financial officer instrument define right holder longterm debt company subsidiary exhibit number file total security authorize instrument take individually exceed total asset company subsidiary consolidate basis company agree furnish copy instruments commission request exhibit merck co inc deferral program amend restate november table content article administration article ii eligibility article iii deferral defer compensation account article iv valuation defer compensation account article v redesignation deferred compensation account article vi distribution defer compensation account article vii deduction distribution article viii beneficiary designation article ix amendment schedule deferral program investment alternative schedule ii special provision applicable medco health employee imerck co inc deferral program deferral program program intend permit select group management defer income immediately payable annual base salary incentive plan merck co inc company administration program administer compensation benefit committee company board director committee compose nonemployee directors committee shall responsibility determine investment available program investment shall list schedule hereto committee shall review investment selection year committee shall decision affect timing price defer compensation participant subject section security exchange act amend section officer delegate authority program ii eligibility eligibility defer program determine accordance term company base salary deferral plan incentive plan committee authority refuse permit employee participate program committee determine participation jeopardize program compliance applicable law program status hat plan employee retirement income security act iii deferral defer compensation account election defer participant decision defer program base salary deferral plan prior commencement pay period base salary defer earn ii annual incentive plan prior commencement performance year bonus monie defer earn iii longterm incentive plan prior commencement year award period bonus monie defer earn purpose annual incentive plan participant hire company performance year election later thirtieth th day participant date hire defer bonus monie earn performance year base salary deferral plan amount equal excess percent annual base salary define base salary deferral plan equal less percent annual base salary participant annual base salary excess determine section internal revenue code defer annual longterm incentive plan amount excess defer amount defer know deferred compensation credit participant defer compensation account defer compensation shall hold account regardless plan base salary deferral incentive plan defer b election distribution schedule time election participant shall elect distribution schedule hisher defer compensation participant election distribution schedule connection deferral election annual andor longterm incentive plan shall time participant make election defer participant initial election distribution schedule connection deferral base salary deferral plan shall time initial deferral election shall irrevocable calendar year shall apply deferral annual base salary new distribution election effective election different distribution schedule connection deferral base salary deferral plan time provide new distribution schedule shall apply prospectively deferral annual base salary follow calendar year distribution schedule participant elect payment begin participant actual retirement date subsequent date prior thereto participant elect lump sum schedule annual installment maximum annual installment installment payable year participant termination employment c election investment alternative participant shall designate accordance procedure establish company designation portion multiple defer compensation allocate investment alternative available program iv valuation defer compensation account common stock initial crediting allocate merck common stock shall determine number partial share merck common stock purchase closing price merck common stock new york stock exchange date cash payment base salary amount defer base salary deferral plan incentive award amount defer incentive plan pay participant deferral date committee determine valuation deferral date constitute fair market value committee shall decide date fair market value shall determine valuation method set forth paragraph company shall credit participant defer compensation account number partial share merck common stock determine time prior delivery share shall share purchase earmarked account participant shall right shareholder respect share credit hisher defer compensation account dividend company shall credit participant defer compensation account number partial share merck common stock purchasable closing price merck common stock new york stock exchange date dividend pay common stock dividend pay number share credit account include pro rata dividend partial share share credit issue outstanding redesignation value merck common stock purpose redesignation shall closing price merck common stock new york stock exchange day redesignation request receive pursuant administrative guideline establish human resource financial service area treasury department provide request receive prior close new york stock exchange day ii follow business day request receive new york stock exchange close distribution distribution merck common stock value closing price merck common stock new york stock exchange distribution date limitation share merck common stock deliver provision program deliver company authorize unissued share common stock common stock hold treasury share available year program shall tenth onepercent outstanding share merck common stock business day precede calendar year plus share authorize program previous year minus share distribute executive incentive plan april adjustment event reorganization recapitalization stock split stock dividend combination share merger consolidation right offering change corporate structure share company number kind share merck common stock available program credit participant defer compensation account shall adjust accordingly b mutual fund initial crediting allocate mutual fund shall determine number partial mutual fund share purchase closing net asset value mutual fund share deferral date company shall credit participant defer compensation account number partial mutual fund share determine mutual fund share shall purchase earmarked account shall participant right shareholder respect mutual fund share dividend company shall credit participant defer compensation account number partial mutual fund share purchasable closing net asset value mutual fund share date dividend pay mutual fund share dividend pay number share credit account include pro rata dividend partial share share own participant purpose computation redesignation value mutual fund share purpose redesignation shall net asset value mutual fund close business day redesignation request receive pursuant administrative guideline establish human resource financial service area treasury department provide request receive prior close new york stock exchange day ii follow business day request receive new york stock exchange close distribution mutual fund distribution value base close net asset value mutual fund share distribution date adjustment event reorganization recapitalization stock split stock dividend combination share merger consolidation right offering change corporate structure share mutual fund number kind share mutual fund credit participant defer compensation account shall adjust accordingly v redesignation deferred compensation account basic redesignation rule participant beneficiary legal representative deceased participant redesignate amount credit deferred compensation account investment available program accordance follow rule eligible participant active employee separate employee retire participant eligible redesignate provide redesignation shall merck common stock frequency time effective june limit number times participant redesignate amount measure mutual fund subject section b merck common stock redesignation shall place day redesignation request receive pursuant administrative guideline establish human resource financial service area treasury department provide request receive prior close new york stock exchange day ii follow business day request receive new york stock exchange close extent redesignation redesignation multiple investment redesignation beneficiary legal representative beneficiary legal representative deceased participant redesignate subject rule participant beneficiary legal representative shall opportunity redesignate merck common stock regard rule set forth section b beneficiary legal representative shall subject redesignation rule participant include limitation redesignation merck common stock b special rule redesignation common stock eligible participant redesignation merck common stock participant balance merck common stock exceed time participant annual base salary purpose section b annual base salary active participant shall participant monthly base salary date redesignation request retire participant monthly base salary date retirement annualize frequency time section officer redesignation merck common stock window period establish company timetotime redesignation amount merck common stock restrict amount excess time annual base salary section officer redesignation amount merck common stock restrict amount hold merck common stock long month material nonpublic information committee sole discretion advice counsel time rescind redesignation merck common stock redesignation participant time redesignation possession material nonpublic information respect company b committee estimation benefit information time hisher redesignation committee determination shall final bind event rescission participant defer compensation account shall return status redesignation occur notwithstanding committee shall rescind redesignation fact review participant general counsel company designee prior redesignation general counsel designee conclude participant possession adverse material nonpublic information c conversion common stock account committee sole discretion convert share merck common stock allocate participant defer compensation account manner provide position terminate retire participant take wish opinion committee uncertain propriety participant continue interest merck common stock date conversion shall date commencement employment date committee action whichever later conversion shall expression value share merck common stock participant defer compensation account expression value united states dollar available investment value merck common stock shall base closing price new york stock exchange date conversion trading take place day business day trading take place conversion paragraph shall irrevocable absolute vi distribution defer compensation account distribution defer compensation account shall accordance participant distribution schedule pro rata investment distribution merck common stock share cash payable partial share subject limitation set forth article iv section section officer distribution amount merck common stock restrict amount hold merck common stock long month distribution mutual fund cash distribution value fifteenth day distribution month day business day business day pay soon practicable retirement participant retirement active service cause distribution hisher defer compensation account commence soon administratively feasible accordance participant previously elect schedule participant retire active service prior age committee establish different distribution schedule schedule choose committee shall short participant previously elect schedule significant change participant economic circumstance attributable participant early retirement committee decide change participant distribution schedule participant defer compensation account distribute ratably year participant retire company request limitation precede sentence apply b death event participant death distribution program commence soon administratively feasible accordance hisher previously elect schedule participant beneficiary legal representative request committee change distribution schedule c automatic distribution participant terminate employment reason death divestiture separation reorganization reduction force elimination participant job position joint venture business entity define section e eligible retire active service company pension plan hisher defer compensation account automatically pay lump sum soon administratively feasible follow hisher termination employment furthermore provide schedule ii participant dies retire active service employment terminate result divestiture separation reorganization reduction force elimination participant job deferred compensation account value date hisher death retirement termination divestiture separation hisher defer compensation account distribute lump sum soon administratively feasible follow hisher death retirement termination divestiture separation termination divestiture separation participant employ subsidiary company sell subsidiary long consider control group company participant shall consider terminate employment company purpose program participant employment terminate result divestiture division subsidiary company result separation reorganization reduction force elimination participant job distribution program commence soon administratively feasible termination employment accordance hisher previously elect schedule schedule committee discretion approve accordance section g e joint venture service participant termination employment order position joint venture business entity company shall directly indirectly percent outstanding voting ownership interest shall consider termination employment company purpose distribution program f hardship distribution committee sole discretion accelerate time distribution participant defer compensation account participant experience severe financial hardship illness accident death immediate family loss damage property casualty extraordinary unforeseeable circumstance participant provide committee statement reasonable detail nature financial hardship statement acceleration necessary alleviate hardship g postretirement postdivestiture postseparation modification participant retire active service employment terminate result divestiture separation describe section submit petition committee request extension period distribution hisher defer compensation account petition received committee prior distribution participant hisher previously elect distribution schedule revise distribution schedule exceed year date actual retirement divestiture separation date effective begin calendar year committee shall event grant new schedule participant cumulatively receive great portion hisher defer compensation account measure end calendar year provide schedule ii participant active employee request paragraph vii deduction distribution company deduct distribution amount require withhold income social security tax purpose withholding pro rata basis investment company deduct amount participant owe company reason viii beneficiary designation participant program designate beneficiary receive hisher defer compensation account participant death beneficiary predecease participant participant beneficiary participant defer compensation account distribute participant estate ix amendment committee amend program time amendment shall materially adversely affect right obligation respect defer compensation theretofore schedule deferral program investment alternative january january merck common stock mutual fund american century emerge market fund american fund europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fund fidelity lowprice stock fund fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income liberty acorn fundclass z pimco foreign bond institutional pimco long term government institutional pimco total return institutional putnam global equity fund putnam international voyager putnam vista rowe price blue chip growth fund vanguard asset allocation september september investment briefly name putnam global growth fund result merger september putnam global equity fund putnam global growth fund merge fund briefly retain putnam global growth fund effective october merge fund change putnam global equity fund schedule deferral program investment alternative effective january july merck common stock mutual fund american century emerge market institutional american fund europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowprice stock fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income liberty acorn class z pimco foreign bond institutional pimco long term government institutional pimco total return institutional putnam global equity putnam international capital opportunity fund putnam vista rowe price blue chip growth vanguard asset allocation prior april know putnam international voyager fund redesignation defer amount measure putnam vista july prior pm et july participant hisher defer compensation account measure putnam vista investment alternative redesignate investment alternative accordance article v section participant redesignate measure putnam vista investment alternative remain investment alternative pm et july putnam vista account shall redesignate pm et july fidelity midcap stock fund schedule deferral program investment alternative effective july november merck common stock mutual fund american century emerge market institutional american fund europacific growth fund columbia acorn fund z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowprice stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income pimco foreign bond institutional pimco long term government institutional pimco total return institutional putnam global equity putnam international capital opportunity fund rowe price blue chip growth vanguard asset allocation prior october know liberty acorn class z prior april know putnam international voyager fund redesignation defer amount measure putnam global equity putnam international capital opportunity fund collectively putnam fund november prior pm et november participant hisher defer compensation account measure putnam fund investment alternative redesignate investment alternative accordance article v section participant redesignate measure putnam fund investment alternative remain investment alternative pm et november putnam fund investment alternative shall redesignate pm et november fidelity retirement money market portfolio schedule deferral program investment alternative effective november merck common stock mutual fund american century emerge market institutional american fund europacific growth fund columbia acorn fund z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowprice stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income liberty acorn class z pimco foreign bond institutional pimco long term government institutional pimco total return institutional rowe price blue chip growth vanguard asset allocation prior october know liberty acorn class z schedule ii special provision applicable medco health employee approve july definition medco health medco health solutions inc medco health employee participant employ medco health prior spinoff ii employ merck prior spinoff expect employ medco health prior spinoff separate medco health employee participant deferral program employ medco health date spinoff consider terminate employment company result spinoff spinoff distribution merck shareholder equity securities medco health spinoff divestiture purpose deferral program special provision notwithstanding contrary article vi section c deferral program defer compensation account separate medco health employee shall pay accordance article vi section regard threshold set forth section c notwithstanding contrary article vi section g deferral program medco health employee submit petition extension distribution schedule permit section g prior spinoff medco health employee separated medco health employee provide medco health employee make request new distribution schedule prior spinoff separate medco health employee request shall effective exhibit merck co inc plan defer payment director compensation amend restate november table content article purpose article ii election deferral measurement method distribution schedule article iii valuation defer amount article iv redesignation deferral account article v payment defer amount article vi designation beneficiary article vii plan amendment termination schedule measurement method imerck co inc plan defer payment director compensation purpose provide arrangement director merck co inc current employee elect voluntarily defer payment annual retainer meeting committee fee termination service director ii value compensation mandatorily defer behalf ii election deferral measurement method distribution schedule election voluntary deferral prior december year director entitle irrevocable election defer termination service director receipt payment retainer month begin april calendar year b committee chairperson retainer begin april calendar year c meeting committee fee month begin april calendar year prior commencement duty director director newly elect appoint board calendar year election paragraph portion voluntary deferral applicable director year service thereof voluntary deferral shall credit follow meet committee fee defer credit day director services render board retainer andor committee chairperson retainer defer prorata share defer retainer credit business day calendar quarter date voluntary deferral part thereof credit director defer account hereinafter refer voluntary deferral date b mandatory deferral friday follow company annual meeting stockholder friday hereinafter refer mandatory deferral date director credit equivalent onethird annual cash retainer month period begin april precede annual meeting mandatory deferral mandatory deferral measure merck common stock account director newly elect appoint board mandatory deferral date credit pro rata portion mandatory deferral applicable director year service thereof pro rata portion shall credit director account day director service c election measurement method annual election refer section shall include election measurement method method value amount defer measured accordance article iii available measurement method set forth schedule hereto election distribution schedule annual election refer section shall include election receive payment follow termination service director voluntary deferral amount mandatory deferral amount lump sum immediately year termination quarterly annual installment year iii valuation defer amount common stock initial credit annual mandatory deferral shall determine number partial share merck common stock purchase closing price common stock new york stock exchange mandatory deferral date portion voluntary deferral allocate merck common stock shall determine number partial share merck common stock purchase closing price common stock new york stock exchange applicable voluntary deferral date determined committee corporate governance board director measurement merck common stock mandatory voluntary deferral date constitute fair market value committee shall decide date fair market value shall determine valuation method set forth article iii section time deferral period share merck common stock purchase earmark defer amount right shareholder exist respect amount dividend director account credit additional number partial share merck common stock purchasable dividend share previously credit account closing price common stock new york stock exchange date dividend pay distribution distribution merck common stock account value closing price merck common stock new york stock exchange distribution date b mutual fund initial crediting allocate mutual fund shall determine partial mutual fund share purchase closing net asset value mutual fund share mandatory voluntary deferral date whichever applicable director account credit number partial mutual fund share determine time deferral period mutual fund share purchase earmark defer amount right shareholder exist respect amount dividend director account credit additional number partial mutual fund share purchasable close net asset value mutual fund share date dividend pay mutual fund share dividend pay number share previously credit account include pro rata dividend partial share distribution mutual fund distribution value base close net asset value mutual fund share distribution date c adjustment event reorganization recapitalization stock split stock dividend combination share merger consolidation right offering change corporate structure share company mutual fund number kind share unit investment measurement method available plan credit director account shall adjust accordingly iv redesignation deferral account general director request change measurement method value portion hisher account merck common stock amount defer merck common stock method earning attributable deferral redesignate change effective day redesignation request receive pursuant administrative guideline establish human resource financial service area treasury department provide request receive prior close new york stock exchange day ii follow business day request receive new york stock exchange close b redesignation occur active service limit number time director redesignate portion hisher defer account permit redesignated request shall irrevocable designate percentage dollar death follow death director legal representative beneficiary director redesignate subject rule active director set forth article iv section b c valuation amount redesignate portion director account redesignate value cash equivalent cash equivalent convert share unit measurement method purpose redesignation cash equivalent value mutual fund share shall close net asset value mutual fund day redesignation request receive pursuant administrative guideline establish human resource financial service area treasury department provide request receive prior close new york stock exchange day ii follow business day request receive new york stock exchange close v payment defer amount payment payment director amount defer cash accordance distribution schedule elect director pursuant article ii section distribution shall pro rata measurement method distribution shall value fifteenth day distribution month day business day business day pay soon possible b change distribution schedule prior termination request director time calendar year immediately precede calendar year service director expect terminate committee corporate governance board directors committee sole discretion authorize extension payment period originally elect director exceed allowable article ii section andor b payment frequency different originally elect director request regard amount defer december merck common stock method earning attributable deferral deferral merck common stock december earning thereon distribute accordance schedule elect director article ii section determine committee corporate governance article vi c posttermination change distribution schedule follow termination service director director request extension period distribution hisher defer compensation request received committee corporate governance prior distribution participant hisher previously elect distribution schedule revise distribution schedule exceed deferral period allowable article ii section c request grant new payment schedule determine sole discretion committee corporate governance request regard amount defer december merck common stock method earning attributable deferral retire director subject income tax petition committee corporate governance change payment frequency include lump sum distribution committee corporate governance grant petition discretion consider reasonable justification therefor deferral merck common stock december earning thereon distribute accordance schedule elect director article ii section determine committee corporate governance article vi forfeiture director defer attributable mandatory deferral earning thereon shall forfeit removal director determination committee corporate governance sole discretion director join board manage operate participate material way enter employment perform consulting service connect material manner company corporation enterprise firm limited partnership partnership person sole proprietorship business entity determine committee corporate governance sole discretion competitive business company subsidiary affiliate competitor ii directly indirectly acquire equity interest percent great competitor iii disclose material trade secret material confidential information include customer list relate company business company include competitor vi designation beneficiary event death director defer date death shall pay name beneficiary beneficiary designate director beneficiary designate director legal representative installments committee corporate governance sole discretion determine vii plan amendment termination committee corporate governance shall right amend terminate plan time reason schedule measurement method january january merck common stock mutual fund american century emerge market fund american century europacific growth fund fidelity destiny fidelity dividend growth fidelity equity income fund fidelity lowprice stock fund fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income liberty acorn z pimco foreign bond institutional pimco long term government institutional pimco total return institutional putnam global equity fund putnam international voyager putnam vista rowe price blue chip growth fund vanguard asset allocation september september investment briefly name putnam global growth fund result merger september putnam global equity fund putnam global growth fund merge fund briefly retain putnam global growth fund effective october merge fund change putnam global equity fund schedule measurement method effective january july merck common stock mutual fund american century emerge market institutional american fund europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowprice stock fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income liberty acorn class z pimco foreign bond institutional pimco long term government institutional pimco total return institutional putnam global equity putnam international capital opportunity fund putnam vista rowe price blue chip growth vanguard asset allocation prior april know putnam international voyager fund redesignation defer amount measure putnam vista july prior pm et july participant hisher account measure putnam vista measurement method redesignate measurement method accordance article iv participant redesignate measure putnam vista measurement method remain measurement method pm et july putnam vista account shall redesignate pm et july fidelity midcap stock fund schedule measurement method effective july november merck common stock mutual fund american century emerge market institutional american fund europacific growth fund columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowprice stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income pimco foreign bond institutional pimco long term government institutional pimco total return institutional putnam global equity putnam international capital opportunity fund rowe price blue chip growth vanguard asset allocation prior october know liberty acorn class z prior april know putnam international voyager fund redesignation defer amount measure putnam global equity putnam international capital opportunity fund collectively putnam fund november prior pm et november participant hisher defer compensation account measure putnam fund investment alternative redesignate investment alternative accordance article iv participant redesignate measure putnam fund investment alternative remain investment alternative pm et november putnam fund investment alternative shall redesignate pm et november fidelity retirement money market portfolio schedule measurement method effective november merck common stock mutual fund american century emerge market institutional american fund europacific growth columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowprice stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan equity index franklin smallmid cap growth janu enterprise janu growth income pimco foreign bond institutional pimco long term government institutional pimco total return institutional rowe price blue chip growth vanguard asset allocation prior october know liberty acorn class z exhibit december dr peter kim baskin road lexington dear peter pleasure offer position executive vice president research development merck research laboratory grade merck co inc merck company gross base salary month subject appropriate tax payroll withholding deduction effective february position primary work location west point pa merck research laboratory salary employee currently pay monthly basis specific detail offer include follow soon practicable commencing employment merck february receive onetime signon bonus net income taxis require pay voluntarily terminate employment merck ie resign month start date require reimburse company prorate portion bonus eligible consideration merck co inc incentive stock plan stock option purchase merck stock approximate market price date option grant subject term specific option grant option holder purchase stock vest period currently year original option price number share grant determined year company assume begin employment february grant nonqualified stock option grant share merck stock company make annual stock option grant begin employment february grant issue quarterly stock option grant date fall calendar quarter follow date hire describe paragraph option grant term condition include vest term apply generally annual grant applicable year grade employee option grant prior vest immediately termination company employment company prior reason gross misconduct ii termination employment company prior usual vest date grant company fail appoint succeed dr edward scolnick president mrl b appoint president mrl option special vest term vest result ii year accelerate vest date option exercise option addition company terminate employment reason grossmisconduct period effective date raymond v gilmartins retirement second anniversary retirement option grant prior termination date vest termination date shall vest immediately termination date exercisable year purpose letter gross misconduct mean unauthorized disclosure information know proprietary confidential embezzlement theft misappropriation merck asset falsification record report deliberate reckless action cause actual potential injury loss company employee company failure carry assign duty notice writing failure correct result termination employment illegal act company property represent company eligible annual consideration receive cash bonus company executive incentive plan eip grade hire opportunity calendar day employment elect defer cash bonus receive performance year day period represent opportunity elect deferral option performance year opportunity limit new hire grade subject taxis performance year january december bonus pay follow march bonus performance year gross subject appropriate tax payroll withholding deduction assume begin employment february future increase salary continue participation executive incentive plan base annual performance administer performance management plan accordance company compensation policy eligible participate exceptional flexible benefit program include follow plan medical dental life insurance accidental death dismemberment insurance survivor income benefit dependent life insurance longterm disability insurance longterm care insurance financial planning program tax free account health care reimbursement dependent care reimbursement feel free contact steve g sheehan vice president mrlisww license human resource directly need detail benefit program additionally eligible participate employee saving security plan taxdeferre k plan companypaid pension plan presently taxqualifie plan roll eligible distribution plan k plan taxdeferre k plan manage fidelity investment include wide variety investment option eligible day vacation annually accordance company policy accrue monthly basis write acceptance offer defray reasonable relocation expense incurred consist limited cost fee include professional fee incur negotiating agreement terminate employment howard hughes medical institute dispose residence massachusetts move personal household effect permanent residence new location currently home intend purchase new location contact realtor receive list authorize broker relocationdepartment relocation consultant contact directly review relocation benefit proper arrangement question specifically relocation benefit prior consultant contact barbara turansky merck co inc west point pennsylvania note arrangement carrier handle directly merck relocation allowance subject federal income tax accordance federal statute home assistance program base need approve provide directly merck authorize mortgage company behalf addition fund payment home assistance program apply offset mortgage balance program consider second mortgage result lien place property close simultaneously mortgage lien subsequent taxis fund cover period year appropriate taxis deduct monthly payroll leave merck lien taxis satisfied obligate repay prorate portion original home assistance program complete detail program include list mortgage company provide relocation counselor advise offer contingent follow successfully complete drug screen evaluation proof eligibility work united states contingency meet confirm offer february start date employment merck subject merck term condition employment provide offer confirm advise alter current employment status contingency meet order schedule preplacement health evaluation drug screen contact dr robert falcone corporate medical director employee health service merck co inc whitehouse new jersey great deal confidence extend offer impressed achievement strong motivation successful scientific career believe possess quality complement contribute attainment research goal certain merck provide environment stimulate rewarding expectation merck succeed dr edward scolnick president mrl succeed dr edward scolnick president mrl choose return academia employee merck employee mean merck terminate employment relationship time lawful reason order accommodate concern return academia merck agree appoint merck succeed dr edward scolnick president mrl appoint merck succeed dr scolnick president mrl prior second anniversary effective date raymond v gilmartins retirement employment terminate merck reason gross misconduct merck shall onetime grant academic institution designate sole purpose enable set maintain research laboratory employee institution provide designate institution hire employee later year contingency occur purpose grant provide significant benefit condition precedent merck implementation special arrangement termination merck employment sign comply noncompete nondisclosure provision waiver release claim format prescribe merck provide term provision applicable shall favorable term prescribe merck depart mrl employee grade precede year favorable depart employee look forward receive favorable response write sincerely hope find merck co inc career opportunity seek appreciate receive write reply soon possible later december nd answer question provide assistance way hesitate contact sincerely edward scolnick note benefit bonus stock option provide grant subject term applicable plan document plan amend time time company copy susan paulosky steve g sheehan ginny stephens kenneth j weiss wendy l yarno new employee administrationexhibit merck co inc subsidiarie computation ratio earning fix charge million ratio datum year end december income continue operation taxis add subtract onethird rent interest expense gross interest capitalize net amortization equity income loss affiliate net distribution prefer stock dividend net tax earning continue operation onethird rent interest expense gross prefer stock dividend fix charge continue operation ratio earning fix charge continue operation purpose compute ratio earning consist income taxis onethird rent deem company representative interest factor inherent rent interest expense net amount capitalize equity income loss affiliate net distribution dividend prefer stock subsidiary company fix charge consist onethird rent interest expense report company consolidate financial statement dividend prefer stock subsidiary companiesexhibit financial section content financial review description merck business overview competition health care environment operating result select joint venture affiliate information capital expenditure analysis liquidity capital resource critical accounting policy matter recently issue accounting standard cautionary factor affect future result cash dividend pay common share common stock market price condense interim financial datum consolidate statement income consolidate statement retain earning consolidate statement comprehensive income consolidate balance sheet consolidate statement cash flow note consolidated financial statement management report report independent auditor audit committee report compensation benefit committee report select financial datum financial review description merck business merck global researchdriven pharmaceutical product company discover develop manufacture market broad range innovative product improve human animal health directly joint ventures merck sell product primarily drug wholesaler retailer hospital clinic government agency manage health care provider health maintenance organization institution companys professional representative communicate effectiveness safety value product health care professional private practice group practice manage care organization august merck complete spinoff medco health solutions inc medco health follow spinoff company prior period consolidate statement income cash flow relate discussion restate present result medco health separately discontinue operation result spinoff product sale reflect sale medco health thirdparty sale base net selling price merck medco health prior year amounts restate conform current year presentation overview merck remain committed strategy discover develop novel medicine vaccine confident ability drive longterm shareholder value company withdraw product latephase clinical trial despite setback merck research development effort continue foundation company continue focus develop launch novel medicine vaccine back prove outcome competitive price aggressively pursue external alliance lower company cost structure maximize inline franchise allow merck grow succeed long term company complete successful spinoff medco health increase ownership banyu pharmaceutical co ltd banyu japans pharmaceutical company action merck focus pharmaceutical research company strong position japan world secondlarg market november food drug administration fda accept file new drug application nda merckscheringplough pharmaceutical partnership merck scheringplough corporation scheringplough vytorin contain active ingredient zetia ezetimibe zocor simvastatin investigational cholesterollowere medicine develop reduction elevate cholesterol level hypercholesterolemia december merck resubmitte expand nda fda arcoxia new coxib treatment osteoarthritis rheumatoid arthritis chronic low pain acute pain dysmenorrhea acute gouty arthritis ankylose spondylitis merck co inc annual report addition submission merck novel vaccine candidate diabete drug drug sleep disorder latestage pipeline company preclinical phase ii program span significant number therapeutic category include work area diabetes obesity alzheimer disease respiratory disease coronary heart disease rheumatoid arthritis vaccine new technology merck potential compound candidate later stage development fast merck supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound company accelerate effort fundamentally low cost structure companywide initiative october merck announce reduction position expect complete addition fourth quarter company implement new distribution program wholesaler moderate fluctuation sale cause wholesaler investment buying improve efficiency distribution merck pharmaceutical product merck major inline franchise rank class worldwide sale success drive largely merck focus develop novel medicine demonstrate value prove health outcome merck strong financial profile enable company fully fund research development aggressively focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder earning common share assume dilution continue operation include impact implementation new distribution program wholesaler restructure cost relate position elimination continue operation exclude result medco health company anticipate fullyear earning common share assume dilution include effect restructuring cost competition health care environment market company conduct business highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access united states government significant progress expand health care access add prescription drug coverage medicare begin implement voluntary drug discount card medicare beneficiary effective june implementation new benefit support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time benefit design assure prescription drug cost control competitive pressure encourage appropriate use medicine company take leadership role contribute success new medicareendorsed discount card provide medicine free lowincome medicare beneficiary exhaust transitional assistance allowance medicareendorse drug discount card action consistent company longstande patient assistance program provide free medicine patient unite states lack drug coverage afford medicine address cost containment outside medicare company continue effort demonstrate medicine help save cost overall patient health care addition pricing flexibility company product portfolio encourage grow use medicine mitigate effect increase cost pressure outside united states difficult environment encumber government cost containment action company work partnership payer allocate scarce resource optimize health care outcome limit potentially detrimental effect government policy sale growth support discovery development innovative product benefit patient company work government emerge market latin america asia encourage increase investment health improve citizen access medicine country european union eu recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative european commission proposal complete single market pharmaceutical improve competitive climate variety mean include market deregulation company commit improve access medicine enhance quality life people world merck african comprehensive hivaids partnership achap botswana collaboration government botswana bill melinda gates foundation strive develop comprehensive sustainable approach hiv prevention care treatment catalyze access hiv medicine develop country october company begin introduce new mg tablet formulation antiretroviral medicine stocrin price dollar day develop country hard hit hivaids epidemic end patient develop country treat antiretroviral regimen contain crixivan stocrin action merck work partner public private sector alike focus real barrier access medicine develop world need sustainable financing increase international assistance additional investment education training health infrastructure capacity develop country increase focus privacy issue country world include united states eu united states federal state government pursue legislative regulatory initiative patient privacy include recently issue federal privacy regulation concern health information affect company operation predict outcome legislative regulatory advocacy initiative company wellpositione respond evolve health care environment market force company anticipate worldwide trend cost containment continue result ongoing pressure health care budget company continues successfully launch new product contribute health care debate monitor reform new product policy strategy enable maintain strong position change economic environmentmerck co inc annual report operating result sale worldwide sale increase total reflect favorable effect foreign exchange favorable effect price change overall increase reflect strong growth singulair asthma seasonal allergic rhinitis fosamax osteoporosis cozaar hyzaar high blood pressure contribute increase sale vioxx arcoxia arthritis pain cancidas infection cosopt glaucoma proscar benign prostate enlargement maxalt migraine revenue company relationship astrazeneca lp azlp add overall growth domestic sale increase foreign sale grow sale united states unfavorably impact implementation new distribution program wholesaler describe foreign sale negatively affect loss basic patent protection zocor modify cholesterol canada certain country europe include united kingdom germany foreign sale represent total sale historically anticipation possible price increase certain wholesaler place noncancellable order price remain effect merck ship product fourth quarter company implement new distribution program wholesaler moderate fluctuation sale cause wholesaler investment buying improve efficiency distribution merck pharmaceutical product new program lower previous limit average monthly purchase merck pharmaceutical product customer overall implementation new wholesaler distribution program estimate million unfavorable impact consolidate revenue estimate million unfavorable effect zocor sale worldwide sale increase total volume basis foreign exchange onehalf point unfavorable effect sale growth price change essentially effect growth foreign sale represent total sale sale category company product follow million atherosclerosis hypertensionheart failure antiinflammatoryanalgesic osteoporosis respiratory vaccinesbiological antibacterialantifungal ophthalmological urology human immunodeficiency virus hiv present net rebate discount company product include therapeutic preventive agent generally sell prescription treatment human disorder atherosclerosis product zocor largestselle hypertensionheart failure product significant cozaar hyzaar vasotec antiinflammatoryanalgesic include vioxx arcoxia agent specifically inhibit cox enzyme responsible pain inflammation coxibs osteoporosis product fosamax treatment prevention osteoporosis respiratory product singulair leukotriene receptor antagonist treatment asthma relief symptom seasonal allergic rhinitis vaccinesbiological mmr ii pediatric vaccine measle mump rubella varivax live virus vaccine prevention chickenpox recombivax hb hepatitis b vaccine recombinant largestselle antibacterialantifungal product include primaxin new product cancida invanz ophthalmological cosopt trusopt largestselling urology product proscar treatment symptomatic benign prostate enlargement hiv product include crixivan stocrin treatment human immunodeficiency viral infection adult primarily include sale human pharmaceutical pharmaceutical animal health supply sale company joint venture revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively zocor merck statin modifying cholesterol achieve worldwide sale billion decline implementation new wholesaler distribution program unfavorably impact zocor sale approximately million year sale zocor affect increase competition statin market loss basic patent protection canada certain country europe include united kingdom germany patent expiration unfavorable impact sale comparison mailorder adjust prescription level zocor increase approximately april fda approve new indication zocor base result landmark heart protection study hps demonstrate thatalong diet zocor mg cholesterollowere medication prove save life reduce risk heart attack stroke people heart disease diabete regardless cholesterol level result subgroup analysis hps publish june issue lancet show treatment zocor mg lower incidence heart attack stroke people diabete regardless cholesterol glucose level merck continue communicate result landmark hps physician consumer merck co inc annual report new contract take effect zocor select sole highpotency hmg agent statin department veteran affairs department defense high potency define contract lower ldlc zocor lose market exclusivity united states company expect decline sale fosamax prescribe medicine worldwide treatment postmenopausal male glucocorticoidinduce osteoporosis continue strong growth sale billion increase mailorderadjuste prescription level fosamax increase approximately fosamax weekly launch market worldwide potential continue growth osteoporosis market remain strong few woman osteoporosi seven major market diagnose treat april international study publish archive internal medicine show woman stop hormone replacement therapy hrt experience significant bone loss year follow discontinuation study show fosamax prevent bone loss woman helped increase bone density spine maintain bone density hip postmenopausal woman stop hrt june publish study versus actonel administer approve oncedaily dose regimen europe study conduct fosamax mg weekly provide significantly great increase bone mineral density spine hip similar tolerability september result headtohead study present annual meeting american society bone mineral research study efficacy fosamax vs evista comparison trial effect demonstrate superiority fosamax versus evista raloxifene treatment postmenopausal osteoporosis fosamax mg weekly provide significantly great increase bone mineral density spine hip raloxifene mg daily global sale cozaar companion agent hyzaar combination cozaar diuretic hydrochlorothiazide treatment hypertension strong reach billion increase mailorderadjuste prescription level cozaar hyzaar increase approximately cozaar hyzaar compete fastestgrowe class antihypertensive market cozaar secondmostfrequently prescribe angiotensin ii antagonist aiia united states largestselle aiia europe march fda approve cozaar aiia indicate reduce risk stroke patient hypertension leave ventricular hypertrophy lvh new indication base landmark losartan intervention endpoint reduction hypertension life study life study demonstrate treatment regimen base cozaar reduce risk stroke patient hypertension lvh versus treatment regiman base beta blocker atenolol study black patient hypertension lvh low risk stroke atenolol cozaar separate set hypertension guideline issue seventh report joint national committee prevention detection treatment high blood pressure united states european society hypertensioneuropean society cardiology guidelines europe june support use aiias treatment certain group patient base landmark life reduction endpoint non insulin dependent diabete mellitus angiotensin ii antagonist losartan renaal study cozaar renaal study patient hypertension type ii diabetes nephropathy cozaar significantly delay double serum creatinine marker kidney disease significantly delay progression endstage renal disease esrd condition require dialysis renal transplantation survival effect overall mortality cozaar medicine demonstrate significant reduction risk esrd patient type ii diabetes nephropathy hypertension thirtytwo country grant new regulatory license cozaar base life study country base renaal merck ei du pont de nemour company dupont begin share equally operate profit cozaar hyzaar north america term license agreement establish party financial term outside north america change worldwide sale vioxx merck onceaday coxib grew achieve billion sale mailorder adjust prescription level vioxx decrease approximately vioxx remain widely available coxib manage care formulary united states vioxx coxib united states offer hour pain relief oncedaily tablet indication million prescription write united states introduction outside united states vioxx bestselle arthritis pain medicine datum present th annual scientific meeting american academy neurology april profile research result vioxx treatment acute migraine headache vioxx mg daily mg daily relieve acute migraine pain hour reduce certain symptom associate migraine headache moderate severe intensity vioxx welltolerate compare placebo patient study supplemental nda review fda additional indication acute migraine juvenile rheumatoid arthritis approve use expect enhance efficacy profile vioxx arcoxia merck new coxib continue launch country outside united states december arcoxia launch countries europe latin america asia worldwide sale reach million year merck co inc annual report december company submit nda arcoxia fda seek indication treatment osteoarthritis rheumatoid arthritis chronic low pain acute pain dysmenorrhea acute gouty arthritis ankylose spondylitis painful condition spine fda determine accept merck application submit june new study present annual congress european league rheumatism show arcoxia provide sustained pain relief patient osteoarthritis rheumatoid arthritis treatment effect maintain duration studymore year osteoarthritis study year rheumatoid arthritis study result investigational study arcoxia patient chronic low pain publish august issue journal pain study show arcoxia mg mg daily provide significant improvement relief symptom disability associate chronic low pain compare placebo improvement observe week initiate therapy maximum relief observe week relief maintain threemonth study november european unions committee proprietary medicinal product conclude comprehensive review cox selective inhibitor class include vioxx arcoxia confirm medicine positive balance benefit risk singulair merck onceaday oral medication indicate treatment chronic asthma relief symptom seasonal allergic rhinitis hay fever continue strong performance singulair secondmostprescribe product overall respiratory market united states total sale singulair billion increase mailorderadjuste prescription level singulair increase approximately quarter merck launch new indication singulair relief symptom seasonal allergic rhinitis adult child young year age singulair represent novel way treat seasonal allergy block leukotriene instead histamine offer relief million people united states suffer form allergic rhinitis twentyeight country outside united states approve new indication september merck announce singulair available united states prevention treatment chronic asthma child age month year new convenient onceaday oral granule formulation new formulation represent nonsteroidal oncedaily oral asthma controller medication approve child young month oral granule formulation singulair relief symptom seasonal allergy child age year asthma common chronic childhood illness affect million child united states increase prevalence child year september merck present result new study prevention virally induce asthma previa th annual congress european respiratory society previa show young child asthma trigger cold experience significantly few asthma attack treat singulair compare placebo virus cause common cold respiratory infection account childhood asthma attack march fda approve emend member new class medicine help prevent acute delay nausea vomiting associate highly emetogenic cancer chemotherapy presentation th annual meeting american society clinical oncology demonstrate treatment regimen contain emend reduce impact chemotherapyinduce nausea vomit patient daily function sale growth benefit cancidas new class antifungal call echinocandin glucan synthesis inhibitor introduce decade cancida treat certain lifethreatening fungal infection prevalent number people compromise immune system increase medicine indicate treatment candidemia bloodstream infection follow candida infection intraabdominal abscess peritonitis infection line abdominal cavity pleural space infection infection lining lung indicate esophageal candidiasis invasive aspergillosis patient respond tolerate antifungal therapy amphotericin b lipid formulation amphotericin b andor itraconazole product experience growth include antibiotic primaxin proscar treatment symptomatic benign prostate enlargement maxalt treatment acute migraine headache adult cosopt treat glaucoma propecia male pattern hair loss invanz treatment select moderate severe infection adult crixivan contribute sale decline unit volume result therapeutic competition contribute merck total sale revenue result company relationship azlp primarily relate sale nexium global sale zetia cholesterol absorption inhibitor develop market merckscheringplough pharmaceutical reach million million prescription write united states launch zetia midnovember accord ims health zetia currently account new prescription cholesterolmodifye market zetia reimburse nearly patient manage care plan united states company record interest merckscheringplough partnership equity income affiliate zetia new class come market cholesterol management category statin introduce year ago work low cholesterol unique way inhibit cholesterol absorption intestine zetia combine statin work inhibit cholesterol synthesis liver follow successful completion european union mutual recognition procedure ezetrol brand zetia outside united states launch european countriesgermany united kingdom switzerland sweden netherlandsmerck co inc annual report september merckscheringplough pharmaceutical submit nda fda vytorin contain active ingredient zetia ezetimibe zocor simvastatin approve product single medication target bodys source cholesterol dual inhibitioninhibite cholesterol production liver absorption intestine november filing accept fda standard review similar application file country outside united states cost expense million change change material production marketing administrative research development acquire research equity income affiliate income expense net great material production material production cost increase compare sale growth rate exclude effect exchange inflation cost increase compare sale volume level increase cost relative sale volume reflect effect change product mix change mix domestic foreign sale attributable implementation new distribution program wholesaler material production cost increase compare sale growth rate primarily attributable effect change product mix exclude effect exchange inflation cost increase point high unit sale volume growth gross margin compare market administrative marketing administrative expense increase exclude effect exchange inflation cost increase primarily attributable impact million restructuring cost relate position elimination company accelerate effort fundamentally low cost structure companywide initiative october company announce reduction position expect complete approximately position eliminate december additional restructuring cost expect incur complete cost reduction expect generate annual saving payroll benefit cost million start company continue seek opportunity improve business process reduce cost structure marketing administrative expense decrease total volume basis marketing administrative expense percentage sale research development research development expense increase exclude effect exchange inflation expense increase research development expense growth reflect company ongoing commitment basic clinical research new research collaboration merck latestage pipeline candidate include novel vaccine human papillomavirus hpv pain associate shingles rotateq vaccine rotavirus highly contagious virus common cause severe gastroenteritis infant young child merck expect file product license application pla fda novel vaccine candidate second half compete claim intellectual property hpv field company confident claim delay company program company expect submit pla fda proquad vaccine pediatric combination vaccine measle mump rubella chickenpox second half company study dpiv inhibitor glucoselowering mechanism combination treatment type ii diabetes merck plan enter phase iii clinical trial investigational compound second quarter expect submit nda fda mercks earlystage pipeline include candidate follow area diabetes obesity alzheimer disease respiratory disease coronary heart disease rheumatoid arthritis vaccine company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology merck complete significant transaction include research collaboration preclinical clinical compound technology transaction compare transaction complete include agreement follow company genpath cancer amrad respiratory disease neurogen pain actelion cardiovascular disease february company announce enter agreement h lundbeck lundbeck develop commercializein united states gaboxadol compound license lundbeck party currently phase iii development treatment sleep disorder term agreement lundbeck receive initial payment million million additional milestone payment company lundbeck jointly complete ongoing phase iii clinical program company fund majority remain development activity company anticipate file nda fda late mid follow fda approval company plan copromote gaboxadol united states lundbeck receive share gaboxadol sales united states february company announce agree acquire aton pharma inc aton privately hold biotechnology company focus development novel treatment cancer disease consideration acquisition consist upfront contingent payment base regulatory filing approval sale product aton clinical pipeline histone deacetylase inhibitor represent class antitumor agents potential efficacy base novel mechanism action aton lead product candidate know suberoylanilide hydroxamic acid extensively study phase clinical trial currently phase ii clinical trial treatment cutaneous tcell lymphoma company expect complete acquisition aton quarter merck co inc annual report chart reflect company research pipeline march candidate show phase iii include specific product candidate show phase ii include advanced compound specific mechanism give therapeutic area backup compound regardless phase development additional indication therapeutic area additional line extension formulation inline product show preclinical area show company initiate good laboratory practice glp study compound mechanism distinct phase ii company program generally design focus development novel medicine address large unmet medical need research pipeline preclinical diabetes atherosclerosis parkinson disease pain anxiety osteoporosis cancer rheumatoid arthritis glaucoma antibacterial vaccine phase diabete c obesity c c atherosclerosis c alzheimer disease c c multiple sclerosis c pain c psychiatric disease c respiratory disease c rheumatoid arthritis c c aids c vaccines hiv vaccine phase ii obesity c alzheimer disease c urinary incontinence c respiratory disease c postoperative nausea vomit c vaccines pediatric combination phase iii pediatric combination vaccine proquad rotavirus vaccine rotateq shingles zoster vaccine human papillomavirus hpv vaccine diabete mk q sleep disorder mk gaboxadol submission cardiovascular vytorin ezetimibesimvastatin submit q arthritisanalgesia arcoxia submit q february merck announce discontinued phase ii clinical trial lead gabaa cid cid agonist compound treatment generalize anxiety company continue research field anxiety ongoing study gaba agonist molecules time development molecule certain april merck announce discontinuing development lead phosphodiesterase pde inhibitor compound phase ii clinical trial treatment asthma chronic obstructive pulmonary disease copd company continue research field asthma copd ongoing study pde inhibitor molecule time development molecule certainin august merck announce phase clinical trial lead hiv integrase inhibitor compound hold company continue research field integrase inhibitor ongoing study integrase inhibitor time development molecule certain november company announce discontinuing phase iii clinical development program substance p antagonist investigational product mk treatment depression phase iii clinical program halt compound fail demonstrate efficacy treatment depression merck remain committed neuroscience program november company announce discontinuing phase iii clinical development program investigational product mk treatment diabete merck develop mk collaboration kyorin pharmaceutical co ltd clinical program halt recent finding merck longterm safety assessment program identify rare form malignant tumor mice clinical relevance finding human unknown merck continue commitment diabetes research currently study dpiv inhibitor diabete company plan enter phase iii investigational compound second quarter research development expense increase exclude effect exchange inflation expense increase research development pharmaceutical industry inherently longterm process follow datum unbroken trend yearto year increase company research development spending period compound annual growth rate research development research development expenditure millions merck co inc annual report acquire research company increase ownership banyu strengthen merck position japan world secondlarg pharmaceutical market connection banyu share acquisition company record charge million acquire research associate product development acquisition date technological feasibility establish alternative future use exist equity income affiliate equity income affiliate reflect performance company joint venture partnership return azlp decrease equity income affiliate reflect low partnership return azlp primarily result impact generic competition prilosec decrease equity income affiliate primarily attributable impact company share marketing launch expense zetia ongoing research development expense associate merckscheringplough partnership income expense net increase income net primarily reflect million gain sale aggrastat product right united states low minority interest expense result banyu share acquisition realize gain company investment portfolio relate favorable interest rate environment increase expense net primarily attributable loss investment partially offset low minority interest expense earning million share amount change change income continue operation sale net income average total asset earning common share assume dilution continue operation company effective income tax rate low tax rate result change mix domestic foreign income include impact fourth quarter restructure cost new wholesaler distribution program income continue operation decline compare decline income continue operation percentage sale compare decline ratio drive effect change product mix increase spending research development reduction reflect impact new wholesaler distribution program restructuring cost charge acquire research net income percentage average total asset earning common share assume dilution continue operation decline low relative decline earning common share assume dilution continue operation compare income continue operation result treasury stock purchase select joint venture affiliate information expand research base realize synergy combine capability opportunity asset company form number joint venture note financial statement information company enter agreement astra ab astra develop market astra product united states thecompany astra form equally own joint venture develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach line company astra restructure joint venture company acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical lp partnership company maintain limited partner interest partnership rename astrazeneca lp azlp exclusive distributor product kbi retain right merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning return aggregate million million million respectively decrease attributable reduction preferential return primarily result impact generic competition prilosec merck co inc annual report merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture expand europe canada sale joint venture product follow million gastrointestinal product product merck pasteur mrieux connaught aventis pasteur establish own joint venture market vaccine europe collaborate development combination vaccine distribution europe sale joint venture product follow million hepatitis vaccine viral vaccine vaccine merck rhnepoulenc aventis combine animal health poultry genetic business form merial limited merial fully integrate animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie sale joint venture product follow million fipronil product avermectin product product company scheringplough corporation scheringplough enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area cholesterolmanagement partnership agreement expand include country world exclude japan october ezetimibe new class cholesterollowere agent approve united states zetia germany ezetrol zetia launch united states november follow successful completion european union mutual recognition procedure ezetrol launch european countriesgermany united kingdom switzerland sweden netherlands sale total million million september merckscheringplough pharmaceutical submit nda fda vytorin contain active ingredient zetia zocor november filing accept fda standard review similar application file country outside united states capital expenditure capital expenditure billion billion expenditure unite states billion billion expenditure include million production facility million research development facility million environmental project million administrative safety general site project capital expenditure approve spend december billion capital expenditure estimate billion depreciation billion million million respectively apply location united states capital expenditure millionsanalysis liquidity capital resource merck strong financial profile enable company fully fund research development aggressively focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder cash provide operating activity billion company primary source fund finance capital expenditure acquisition banyu share treasury stock purchase dividend pay stockholder december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment select datum millions work capital total debt total liability equity cash provide operation total debt work capital level adequate meet operating requirement company ratio total debt total liability equity cash provide operation total debt reflect strength company operate cash flow ability company cover contractual obligation merck co inc annual report company contractual obligation december follow payment period million total loan payable current portion longterm debt longterm debt operating lease loan payable current portion longterm debt include million note final maturity annual basis repurchase holder option remarkete agent remarkete redeem company loan payable current portion longterm debt reflect million longdate note subject repayment option holder annual basis require funding obligation relate company pension postretirement benefit plan expect material company billion shelf registration statement file securities exchange commission issuance debt security effective february company issue million threeyear note million variable rate note shelf february company enter interest rate swap contract effectively convert fix rate note float rate instrument remain capacity company shelf registration statement approximately million company strong financial position evidence triplea credit rating moodys standard poor outstanding debt issue provide high degree flexibility obtain fund competitive term ability finance ongoing operation primarily internally generate fund desirable high risk inherent research development require develop market innovative new product highly competitive nature pharmaceutical industry company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation july board director approve purchase time billion merck share company purchase billion treasury share previously authorize complete program million program total treasury stock purchase billion period company purchase million share total cost billion dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge anticipate thirdparty sale expect occur planning cycle typically year future company layer hedge time increase portion sale hedge get close expect date transaction probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow fully offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow weak dollar result net benefit market value company hedge decline million million respectively uniform weaken dollar december market value determine foreign exchange option pricing model hold factor exchange rate constant merck use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset merck routinely enter contract fully offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency themerck co inc annual report company enter forward contract limit basis deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate company minimize effect exchange monetary asset liability manage operating activity net asset position local level company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly strengthen currency exposure company december income continue operation taxis decline million million respectively merck net long position relative major foreign currency consideration forward contract uniform strengthen dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow addition revenue hedge balance sheet risk management program company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party million notional payfloate receivefixe interest rate swap contract designate hedge fair value change million tenyear fiveyear threeyear fix rate note attributable change benchmark libor swap rate swap effectively convert fixedrate obligation floatingrate instrument company party sevenyear combine interest rate currency swap contract enter convert variable rate foreign currency denominate investment variable rate dollar investment swap contract hedge change fair value investment attributable fluctuation exchange rate allow company receive variable rate return cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly impact change interest rate market value company medium longterm fixedrate investment modestly impact change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value company investment debt relate swap contract change interest rate indicate percentage point increase interest rate december positively impact net aggregate market value instrument million million respectively percentage point decrease december negatively impact net aggregate market value million million respectively fair value company debt determine pricing model reflect percentage point shift appropriate yield curve fair value company investment determine combination pricing duration model duration linear approximation work modest change yield generate symmetrical result pricing model reflect convexity priceyield relationship provide great precision reflect asymmetry price movement interest rate change opposite direction impact convexity pronounce longerterm maturity low interestrate environment critical accounting policy matter consolidated financial statement include certain amount base management good estimate judgment estimate determine item provision rebate discount return income taxis depreciable amortizable life pension postretirement benefit plan assumption amount record contingency environmental liability reserve uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement revenue recognition revenue sale product recognize title risk loss pass customer revenue record net provision rebate discount return establish time sale accrual rebate discount cover discount result sale customer intermediary wholesale purchaser rebate owe base contractual agreement legal requirement benefit provider include medicaid final dispense product pharmacy benefit plan participant accrual estimate time sale base available information portion sale rebate discount earn adjust appropriate specific know event reflect prevail contractual discount rate amount accrue rebate discount adjust trend significant event indicate adjustment appropriate accrual adjust reflect actual amount pay credit validation claim datum adjustment material result operation merck co inc annual report pension postretirement benefit plan net pension postretirement benefit cost total million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate annually modify reflect prevail market rate december portfolio highquality aa fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december company change discount rate pension postretirement benefit plan expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset apply adjustment reflect recent capital market experience reference information company develop forwardlooke return expectation asset category weight average expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return remain unchanged pension postretirement benefit plan target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment real estate cash investment portfolio equity weighting consistent longterm nature plans benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost company expect minimum pension funding requirement internal revenue code precede hypothetical change discount rate expect rate return assumption impact company funding requirement unrecognize net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption expect return base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize marketrelated value asset ratably fiveyear period total unrecognized net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amortization total unrecognized net loss companys plan december expect increase net pension postretirement benefit cost approximately million annually contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action note financial statement information company continually evaluate risk assess insurance need relative market cost obtain insurance purchase coverage appropriate provide protection loss company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable feasible predict outcome legal proceeding opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company addition time time federal state regulator seek information practice pharmaceutical industry feasible predict outcome request information company expect inquiry material adverse effect financial position liquidity result operation company company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust feasibility study relate cost assessment remedial technique complete extent potentially responsible party prps jointly severally liable expect contribute determined merck co inc annual report company remediate environmental contamination result past industrial activity certain site take active role identify provide cost worldwide survey initially perform assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate estimate extent contamination site initially preinvestigation stage liability potential cost remediation accrue time definitive information available course investigation andor remedial effort site estimate refined accrual adjust accordingly estimate related accrual continue refine annually company believe compliance material respect applicable environmental law regulation expenditure remediation environmental liability million estimate million year management opinion liability environmental matter probable reasonably estimable accrue total million million december december respectively liabilitie undiscounted consider potential recovery insurer party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year taxis income company effective tax rate base expect income statutory tax rate tax planning opportunity available jurisdiction company operate event significant unusual onetime item recognize expect recognize company operate result tax attributable item separately calculate record time unusual onetime item significant judgment require determine company effective tax rate evaluate tax position company establish reserve despite belief tax return position fully supportable certain position likely challenge succeed company adjust reserve light change fact circumstance close tax audit effective tax rate include impact reserve provision change reserve consider appropriate relate interest rate apply company quarterly operating result tax regulation require item include tax return different time item reflect financial statement result effective tax rate reflect financial statement different report tax return difference permanent expense deductible tax return time difference depreciation expense timing difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion domestic earning million retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability recently issue accounting standard january financial accounting standard board fasb issue interpretation consolidation variable interest entity fin fin require variable interest entity vie consolidated company subject majority risk loss vie activity entitle receive majority entitys residual return december fasb issue revision fin fin r partially delay effective date interpretation march add additional scope exception adoption fin r expect material impact company financial position result operation cautionary factor affect future result annual report write report oral statement time time company contain socalled forwardlooke statement subject risk uncertaintie identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval development program carefully consider statement understand factor cause actual result differ company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially merck co inc annual report company assume obligation update forwardlooke statement carefully evaluate statement light factor describe company filing securities exchange commission especially form k q k item company annual report year end december file march company discuss detail important factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act prior filing year end december reference item company annual report year end december understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie cash dividend pay common share year th q rd q nd q st q common stock market price th q rd q nd q st q high low high low principal market trading common stock new york stock exchange nyse symbol mrk common stock market price information base historical nyse market price adjust reflect spinoff medco health holder merck common stock close business august receive share medco health common stock share merck common stock hold date august merck common stock begin trade postdistribution basis condense interim financial datum million share amount th q rd q nd q st q sale material production cost market administrative expense research development expense acquire research equity income affiliate income expense net income continue operation tax income continue operation income discontinue operation net taxis net income basic earning common share continue operation discontinue operation net income earning common share assume dilution continue operation discontinue operation net income sale material production cost market administrative expense research development expense equity income affiliate income expense net income continue operation tax income continue operation income discontinue operation net taxis net income basic earning common share continue operation discontinue operation net income earning common share assume dilution continue operation discontinue operation net income amount include impact implementation new distribution program wholesaler restructure cost relate position elimination add result round merck co inc annual report consolidate statement income merck co inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development acquire research equity income affiliate income expense net income continue operation taxis taxes income income continue operation income discontinue operation net taxis net income basic earning common share continue operation discontinue operation net income earning common share assume dilution continue operation discontinue operation net income add result round consolidated statement retain earning merck co inc subsidiary year end december million balance january net income common stock dividend declare spinoff medco health balance december consolidate statement comprehensive income merck co inc subsidiary year end december millions net income comprehensive income lossnet unrealize loss gain derivative net tax net income realization net unrealized loss gain investment net tax net income realization minimum pension liability net tax comprehensive income accompany note integral consolidated financial statement merck co inc annual report consolidate balance sheet merck co inc subsidiary december million asset current asset cash cash equivalent shortterm investment account receivable inventory prepaid expense taxis total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress allowance depreciation goodwill intangible net asset liability stockholder equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability minority interest stockholder equity common stock cent par value authorize share issue share share paidin capital retain earning accumulate comprehensive income loss treasury stock cost share share total stockholder equity accompany note integral consolidated financial statement merck co inc annual report consolidate statement cash flow merck co inc subsidiary year end december million cash flow operating activity continue operation net income income discontinue operation net taxis income continue operation adjustment reconcile income continue operation net cash provide operating activity continue operation acquire research depreciation amortization defer income taxis net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity continue operation cash flow invest activity continue operation capital expenditure purchase security subsidiary investment proceed sale security subsidiary investment acquisition banyu share net cash investing activity continue operation cash flow financing activity continue operation net change shortterm borrowing proceed issuance debt payment debt purchase treasury stock dividend pay stockholder proceed exercise stock option net cash financing activity continue operation effect exchange rate change cash cash equivalent discontinue operation net cash provide medco health dividend receive medco health net intercompany settlement cash transfer net cash provide discontinued operation net decrease increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement merck co inc annual report note consolidated financial statement merck co inc subsidiarie million share amount nature operation merck global researchdriven pharmaceutical product company discover develop manufacture market broad range innovative product improve human animal health directly joint venture company product include therapeutic preventive agent generally sell prescription treatment human disorder august merck complete spinoff medco health solutions inc medco health follow spinoff company prior period consolidate statement income cash flow relate disclosure restate present result medco health separately discontinue operation december consolidated balance sheet prior period consolidate statement retain earning comprehensive income relate disclosure restate result spinoff product sale reflect sale medco health thirdparty sale base net selling price merck medco health summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain control interest determine majority ownership interest absence substantive thirdparty participate right consolidate subsidiary merck ownership outside stockholder interest show minority interest investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis foreign currency translation dollar functional currency company foreign subsidiary cash cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory substantially domestic pharmaceutical inventory value low lastin firstout lifo cost market book tax purpose foreign pharmaceutical inventory value low firstin firstout fifo cost market inventory consist currently market product certain product await regulatory approval evaluate realizable value inventory product await regulatory approval company consider probability revenue obtain future sale relate inventory status product regulatory approval process investment investment classified availableforsale report fair value unrealize gain loss extent hedge report net tax minority interest accumulate comprehensive income investment debt security classify heldtomaturity consistent management intent report cost impairment loss charge income expense net otherthantemporary decline fair value company consider available evidence evaluate potential impairment investment include duration extent fair value cost company ability intent hold investment revenue recognition revenue sale product recognize title risk loss pass customer revenue record net provision rebate discount return establish time sale depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate method estimate useful life primarily range year building year machinery equipment office furnishing goodwill intangible goodwill represent excess acquisition cost fair value net asset business purchase effective january company adopt provision statement financial accounting standard goodwill intangible asset fas address recognition measurement goodwill intangible subsequent business combination accordance fas goodwill associate acquisition subsequent june amortize note effective january goodwill exist june amortize assign reporting unit company segment evaluate impairment annual basis fair value base test amortization expense goodwill record report income continue operation increase million basic earning common share continue operation earning common share assume dilution continue operation report net income increase million basic earning common share earning common share assume dilution acquire intangible record cost amortize straightline basis estimate useful life note event circumstance warrant review company assess recoverability future operation intangible undiscounted cash flow derive low appropriate asset grouping generally subsidiary level impairment recognize operating result extent carry value exceed fair value determine base net present value estimate future cash flow merck co inc annual report stockbase compensation employee stockbase compensation recognize intrinsic value method generally employee stock option grant purchase share company stock fair market value time grant accordingly compensation expense recognize company stockbase compensation plan employee performancebase award option grant employee certain equity method investee total significant effect net income earning common share company apply fair value method recognize employee stockbase compensation follow year end december net income report compensation expense net tax report fair value method pro forma net income earning common share continue operation assume dilution report assume dilution pro forma earning common share basic report basic pro forma assume dilution report assume dilution pro forma connection medco health spinoff option grant medco health employee prior february option grant february fully vested accordance original term grant result pro forma compensation expense reflect accelerate vest option addition certain stock option grant medco health employee convert medco health option term amount maintain option holder position pro forma compensation expense option reflect date spinoff average fair value employee nonemployee director option grant respectively fair value estimate blackschole optionprice model base weighted average market price grant date follow weight average assumption year end december dividend yield riskfree interest rate volatility expect life year use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate determine item provision rebate discount return income taxis depreciable amortizable life pension postretirement benefit plan assumption amount record contingency environmental liability reserve uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation acquisition discontinue operation restructure january company wholly own subsidiary msd japan co ltd launch tender offer acquire remain common share banyu pharmaceutical co ltd banyu march company receive tender million share bring ownership outstanding banyu common share purchase price approximating billion october company complete second tender offer remain share banyu bring merck ownership outstanding banyu common share offer purchase price approximating million acquisition allow company enhance position japanese market world secondlarg pharmaceutical market company acquisition banyu share account purchase method accordingly banyus result operation include company consolidated result operation march october respectively pro forma information provide impact transaction material effect company consolidated result operation aggregate purchase price allocate base fair value portion asset liability acquire allocation aggregate purchase price result reversal billion minority interest liability recognition million intangible million goodwill million defer income tax liability million net asset principally property plant equipment intangible include million inline product right year weight average useful life million represent year life tradename connection transaction company record charge million acquiredmerck co inc annual report research associate product development acquisition date technological feasibility establish alternative future use exist approximately million total acquire research charge relate merck product banyu develop sale japanese market significant vioxx product merck choose exclusively license right banyu event generally reimburse banyu associate research development expenditure accordingly product value cost approach adjust reflect probability regulatory approval remain portion acquire research charge represent banyu develop product candidate fair value product determine base present value project future cash flow utilize income approach reflect appropriate riskadjuste discount rate base applicable product stage completion probability technical marketing success july company complete acquisition rosetta inpharmatics inc rosetta lead informational genomics company taxfree reorganization rosetta design develop unique technology efficiently analyze gene datum predict medical compound interact different kind cell body allow merck scientist precisely select drug target potentially accelerate development process acquisition account purchase method accordingly rosetta result operation include company acquisition date pro forma information provide transaction material impact company result operation financial position accordance agreement plan merger agreement share outstanding rosetta stock convert share merck stock result issuance company approximately million share common stock aggregate purchase price transaction approximate million include million common share value million represent employee stock option value agreement date million estimate transaction fee allocation purchase price result tangible asset million consist primarily cash shortterm investment intangible asset million liability assume million include defer tax liability million associate intangible asset goodwill total million intangible weight average useful life approximate year aggregate major class include million patent right million contractual agreement accordance fas goodwill associate rosetta acquisition amortize august merck complete spinoff medco health spinoff effect way pro rata dividend merck stockholders holders merck common stock close business august receive dividend share medco health common stock share merck common stock hold date fractional share medco health common stock issue shareholder entitle fractional share medco health common stock distribution receive cash value instead base letter ruling merck receive internal revenue service receipt medco health share distribution taxfree federal income tax purpose cash receive lieu fractional share taxable prior spinoff merck receive billion dividend medco health merck pay million settlement net intercompany payable medco health addition date spinoff million cash cash equivalent include net asset medco health spin summarize financial information discontinue operation follow year end december total net revenue income taxis taxis income include operation august follow summary asset liability discontinue operation spin august asset cash cash equivalent current asset property plant equipment net goodwill intangible net asset liabilitie current liability longterm debt defer income taxis net asset transfer company accelerate effort fundamentally low cost structure companywide initiative october company announce reduction position expect complete approximately position eliminate december company record restructuring cost million marketing administrative expense million relate employee severance benefit million relate curtailment settlement termination charge companys pension postretirement benefit plan note million relate modification term certain employee stock option grant payment employee severance benefit million leave remain accrue balance million december additional restructuring cost expect incur merck co inc annual report joint venture equity method affiliate merck enter agreement astra ab astra develop market astra product royaltybeare license company total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture company acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning return aggregate million million million respectively decrease attributable reduction preferential return primarily result impact generic competition prilosec astrazeneca merger trigger partial redemption mercks limited partnership interest redemption azlp distribute kbi base primarily multiple merck average annual variable return derive sale astra usa inc product year prior redemption limited partner share agree value conjunction restructure payment million defer astra purchase option asset option buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec asset option exercisable exercise price equal net present value march project future pretax revenue receive company kbi product appraise value merck right require astra purchase interest appraise value addition company grant astra option buy merck common stock interest kbi exercise price base net present value estimate future net sale nexium prilosec option exercisable year astra purchase merck interest kbi product astrazeneca merger constitute trigger event kbi restructuring agreement result merger exchange merck relinquishment right future astra product exist pende patent time merger astra pay million advance payment subject trueup calculation require repayment portion trueup directly dependent fair market value astra product right retain company accordingly recognition contingent income defer realizable determinable anticipate prior provision kbi restructuring agreement trigger event occur sum limit partner share agree value appraise value trueup guarantee minimum billion distribution limited partner share agree value payment trueup occur astrazenecas purchase mercks interest kbi product contingent exercise merck option astrazenecas option payment appraise value occur merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own venture expand europe canada sale product market joint venture million million million merck pasteur mrieux connaught aventis pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale million million million merck rhnepoulenc aventis combine animal health poultry genetic business form merial limited merial fully integrate animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie merial sale billion billion billion merck co inc annual report company scheringplough corporation scheringplough enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area cholesterolmanagement partnership agreement expand include country world exclude japan october ezetimibe new class cholesterollowere agent approve united states zetia germany ezetrol zetia launch united states november follow successful completion european union mutual recognition procedure ezetrol launch european country germany united kingdom switzerland sweden netherlands sale total million million september merckscheringplough pharmaceutical submit new drug application food drug administration fda vytorin contain active ingredient zetia zocor november filing accept fda standard review similar application file country outside united states january merckscheringplough respiratory partnership report result phase iii clinical trial fix combination tablet contain singulair claritin scheringplough nonsedate antihistamine demonstrate sufficient add benefit treatment seasonal allergic rhinitis investment affiliate account equity method include joint venture total billion december respectively amount report asset dividend distribution receive affiliate million million million financial instrument adoption statement financial accounting standard account derivative instrument hedge activity fas january company record favorable cumulative effect accounting change million tax comprehensive income loss represent mark fair value purchase local currency option note cumulative effect accounting change record net income significant foreign currency risk management dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge anticipate thirdparty sale expect occur planning cycle typically year future company layer hedge time increase portion sale hedge get close expect date transaction probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow fully offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow month change option intrinsic value defer accumulate comprehensive income aoci recognition hedged anticipate revenue amount associate option time value exclude designate hedge relationship mark fair value earning significant effective permit fas implementation guidance finalize june designate hedge relationship base total change option cash flow accordingly entire fair value change option defer aoci reclassify sale hedge anticipate revenue recognize hedge relationship perfectly effective hedge ineffectiveness record fair value purchase currency option report account receivable asset primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset merck routinely enter contract fully offset effect exchange exposure merck co inc annual report denominate develop country currency primarily euro japanese yen exposure develop country currency company enter forward contract limit basis deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate company minimize effect exchange monetary asset liability manage operating activity net asset position local level foreign currency denominate monetary asset liability remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate change fair value hedge security fluctuation spot rate offset income expense net fair value change forward contract attributable spot rate fluctuation hedge ineffectiveness material change contract fair value spotforward difference exclude designate hedge relationship recognize income expense net amount significant year end december fair value forward exchange contract report follow balance sheet line item account receivable current portion gain position asset noncurrent portion gain position accrue current liability current portion loss position defer income taxis noncurrent liability noncurrent portion loss position interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk company enter tenyear million notional payfloate receivefixe interest rate swap contract designate hedge fair value change million tenyear fix rate note attributable change benchmark london interbank offer rate libor swap rate company enter similar fiveyear threeyear million notional payfloate receivefixe interest rate swap contract designate fair value hedge million fiveyear threeyear fix rate note swap effectively convert fixedrate obligation floatingrate instrument fair value change note fully offset interest expense fair value change swap contract company party sevenyear combine interest rate currency swap contract enter convert variable rate foreign currency denominate investment variable rate dollar investment interest rate component swap designate hedge currency swap component designate hedge change fair value investment attributable exchange accordingly change fair value investment fluctuation spot rate offset income expense net fair value change currency swap hedge ineffectiveness significant fair value contract report account receivable asset accrue current liability defer income taxis noncurrent liability fair value financial instrument summarize carry value fair value companys financial instrument december fair value estimate base market price available dealer quote carry fair carry fair value value value value asset cash cash equivalent shortterm investment longterm investment purchase currency option forward exchange contract currency swap interest rate swap liabilitie loan payable current portion long term debt longterm debt forward exchange contract currency swap summary carry value fair value company investment december follow carry fair carry fair value value value value availableforsale debt security equity security heldtomaturity security merck co inc annual report summary december gross unrealized gain loss companys availableforsale investment record net tax minority interest aoci follow gross unrealized gross unrealized gain loss gain loss debt security equity security availableforsale debt security heldtomaturity security mature year total billion million respectively december remain debt security billion mature year december million heldtomaturity security mature set million nontransferable note obligation issue company mature concentration credit risk ongoing control procedure company monitor concentration credit risk associate corporate issuer security financial institution conduct business credit risk minimal credit exposure limit establish avoid concentration single issuer institution drug wholesaler represent aggregate approximately onefifth company account receivable december company monitors creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale inventory inventory december consist finished good raw material work process supply total approximate current cost reduction lifo cost recognize inventory asset inventory value lifo method comprise approximately inventory december respectively amount recognize asset consist inventory hold preparation product launch expect sell year reduction finish good primarily attributable spinoff medco health intangible intangible december consist customer relationship medco health patent product right total acquire cost customer relationship medco health patent product right total accumulate amortization aggregate amortization expense record material production expense income expense net total million million million estimate aggregate amortization expense year follow million million million million million loan payable longterm debt commitment loan payable december consist primarily million billion respectively commercial paper borrowing million note annual interest rate reset final maturity annual basis note repurchase holder option remarkete agent remarkete redeem company december loan payable reflect million million respectively longdate note subject repayment option holder annual basis december loan payable include million variable rate borrowing weight average interest rate borrowing december respectively longterm debt december consist astra note note note note euronote debenture debenture debenture variable rate borrowing merck co inc annual report december company party interest rate swap contract effectively convert december fix rate note float rate instrument note december consist primarily million borrowing variable rate average respectively december million million borrowing subject repayment option holder begin respectively year consist foreign borrowing vary rate aggregate maturity longterm debt year follow million billion million million billion rental expense company operating lease net sublease income million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action company continually evaluate risk assess insurance need relative market cost obtain insurance purchase coverage appropriate provide protection loss company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable begin company name number antitrust suit certain certify class action institute nation retail pharmacy consumer state allege antitrust violation action pende state court consolidate pretrial purpose federal court chicago illinois company defendant settle federal class action represent single large group claim time company settle substantially remain case satisfactory term company engage conspiracy admission wrongdoing include settlement agreement feasible predict final outcome remain case opinion company proceeding ultimately result liability material adverse effect company financial position result operation liquidity previously disclose company advise department justice investigate marketing selling activity company pharmaceutical manufacturer connection investigation previously disclose government serve subpoena company production document relate company marketing sale activity subpoena seek substantially information government previously seek company work government respond appropriately subpoena informational request company receive civil investigative demand cid attorney general texas cid seek production document information company marketing selling activity relate texas company working texas attorney general office respond appropriately cid previously disclose company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level judicial panel multidistrict litigation order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like company defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissal plaintiff file amend consolidated class action complaint company defendant company thirty pharmaceutical manufacturer remain defendant similar complaint pende federal court massachusetts file new york county suffolk rockland westchester company believe lawsuit merit vigorously defend previously disclose january department justice notify federal court new orleans louisiana go intervene pende federal false claim act case file seal december company court issue order unseal complaint file physician louisiana ordered complaint serve complaint allege company discount pepcid certain louisiana hospital lead increase cost medicaid company believe complaint merit vigorously defend federal state lawsuit involve numerous individual claim putative class action file company respect vioxx lawsuit defendant pfizer inc market compete product certain lawsuit include allegation gastrointestinal bleed cardiovascular event kidney damage lawsuit file federal court number state court case jurisdiction proceed separately action file state court california new jersey transfer single judge state coordinate proceeding company anticipate lawsuit jurisdiction merck co inc annual report trial half litigation inherently subject uncertainty assurance give outcome give trial company believe lawsuit merit vigorously defend number purport class action lawsuit file individual shareholder united states district court eastern district louisiana naming defendant company current officer company allege defendant false misleading statement company drug vioxx violation federal security law plaintiff request certification class purchaser company common stock october seek unspecified compensatory damage cost suit include attorney fee company believe lawsuit merit vigorously defend company party claim bring consumer protection act united kingdom allege certain child suffer variety condition result vaccinate bivalent vaccine measle rubella andor trivalent vaccine measle mumps rubella include company mmr ii pharmaceutical company sue claimant allege adverse consequence include autism inflammatory bowel disease epilepsy diabetes encephalitis encephalopathy chronic fatigue syndrome connection claim lead case select trial schedule commence april company pharmaceutical company trial case initially limit issue causation defect condition autistic spectrum disorder inflammatory bowel disease early september legal service commission announce decision withdraw public funding litigation bring claimant decision confirm appeal funding review committee september april trial date vacate claim stay pende outcome february hear judicial review funding withdrawal decision company believe lawsuit merit vigorously defend company party individual class action product liability lawsuit claim united states involve pediatric vaccine ie hepatitis b vaccine haemophilus influenza type b vaccine contain thimerosal preservative vaccine defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result thimerosal introduce develop body company successful case dismiss stay ground national vaccine injury compensation program nvicp prohibit person file maintain civil action seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim number similar case mmr ii andor thimerosal contain vaccine file united states court federal claim nvicp determination general causation issue company believe lawsuit claim merit vigorously defend proceeding party time time generic manufacturers pharmaceutical product file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax prilosec vioxx prior expiration company astrazenecas case prilosec patent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patent generic manufacturer receive fda approval market generic form prilosec company file patent infringement suit federal court company file andas generic alendronate rofecoxib astrazeneca company file patent infringement suit federal court company file andas generic omeprazole similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product trial united states respect alendronate daily product conclude november november decision issue district court delaware find company patent valid infringe october court appeal federal circuit affirm validity infringement company basic patent covering use alendronate form request rehear deny trial united states involve alendronate weekly product hold march august district court delaware uphold validity company patent cover weekly administration alendronate result court decision patent valid infringe teva pharmaceuticals usa incs teva abbreviate new drug application filing court decision appeal teva january high court justice england wale hold patent company protect alendronate daily weekly product invalid united kingdom november court appeal england wale affirm rule high court justice england wale protection generic company reference company datum weekly alendronate united kingdom available provision law grant period exclusivity original submitter datum generic company seek judicial review decision licensing authority united kingdom rely company weekly alendronate datum seek approval generic alendronate mg product year approval company weekly alendronate product grant company serve interested party intends appropriate action protect right merck co inc annual report case omeprazole trial court united states render opinion october uphold validity company astrazenecas patent cover stabilize formulation omeprazole rule defendant omeprazole product infringe patent defendant product find infringe formulation patent december court appeal federal circuit affirm decision trial court respect certain generic manufacturer omeprazole product trial date set case rofecoxib anda file include allegation noninfringement invalidity unenforceability company rofecoxib patent previously disclose company file patent infringement lawsuit district court delaware august trial set october previously disclose company name defendant number purport class action lawsuit consolidate single judge shareholder derivative action involve claim relate company revenue recognition practice retail copayment pay individual medco health provide pharmaceutical benefit class action lawsuit amend add claim company medco health certain officer director relate rebate receive medco health medco healths independent status shareholder derivative action amend add arthur andersen llp defendant add certain new allegation relate claim certain individual defendant breach fiduciary duty fail prevent conduct issue previously disclose gruer case discuss antitrust claim pende northern district illinois qui tam action attorney office eastern district pennsylvania intervene medco health complaint seek monetary damage company director defendant lawsuit unspecified injunctive relief spinoff medco health medco health assume responsibility portion potential damage settlement payment pay connection litigation company believe lawsuit merit vigorously defend prior spinoff medco health company medco health agree settle class action basis series lawsuit assert violation employee retirement income security act erisa company medco health certain plaintiff counsel file settlement agreement federal district court new york case commence number plaintiff include participant number pharmaceutical benefit plan medco health pharmacy benefit manager trustee plan consolidated propose class settlement agree plaintiff case gruer case file medco health company propose settlement company medco health agree pay total million medco health agree modify certain business practice continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december court preliminarily approve settlement hold hearing hear objection fairness propose settlement class member representative currently certain class member plan indicate participate settlement court approve settlement determine number class member plan properly elect participate settlement approve settlement final district court grant final approval appeal resolve medco health company agree propose settlement order avoid significant cost distraction protract litigation gruer case similar claim pende pharmaceutical benefit manager allege medco health erisa fiduciary company partyininterest mean erisa plaintiff assert company medco health breach duty engage prohibit transaction result fill prescription company drug increase company market share thing plaintiff demand medco health company disgorge unlawfully obtain profit relief addition case consolidate new york plaintiff allege base essentially factual allegation gruer case medco health company violate federal state racketeering law different plaintiff seek represent california citizens allege medco health company violate california unfair competition law attorney plaintiff indicate assert claim medco health company allege violation sherman act clayton act state antitrust law base allege conspiracy suppress price competition unlawful combination allegedly result high pharmaceutical price spinoff medco health medco health assume substantially liability exposure matter discuss forego paragraph company believe case defend medco health merit legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company addition time time federal state regulator seek information practice pharmaceutical industry feasible predict outcome request information company expect inquiry material adverse effect financial position liquidity result operation company merck co inc annual report company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust feasibility study relate cost assessment remedial technique complete extent potentially responsible party prps jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost worldwide survey initially perform assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate estimate extent contamination site initially preinvestigation stage liability potential cost remediation accrue time definitive information available course investigation andor remedial effort site estimate refined accrual adjust accordingly estimate related accrual continue refine annually management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery insurer party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year prefer stock subsidiary company wholly own subsidiary company issue billion par value variable rate prefer unit unit redeemable par value plus accrue dividend option issuer time addition credit rating company unsecure senior debt obligation fall specify level likelihood company believe remote holder prefer unit ability require redemption prefer unit prefer security hold subsidiary level include minority interest consolidate financial statement connection restructure ami note company assume billion par value prefer stock obligation dividend rate annum carry kbi include minority interest small portion prefer stock carry kbi convertible kbi common share prefer security convertible company common share include common share issuable purpose compute earning common share assume dilution note stockholder equity paidin capital increase million million million respectively increase include million result share issue equivalent employee stock option assume connection rosetta acquisition note remain increase primarily reflect impact share issue exercise stock option relate income tax benefit summary treasury stock transaction share millions follow share cost share cost share cost balance jan purchase issuance balance dec issue primarily stock option plan december million share prefer stock par value authorize issue stock option plan company stock option plan employee nonemployee director employee certain company equity method investee grant option purchase share company common stock fair market value time grant plan approve company shareholder option grant begin generally vest ratably year grant prior generally vest year option expire year date grant company stock option plan employee provide grant performancebase stock award connection medco health spinoff number exercise price outstanding option proportionately adjust maintain option holder position spinoff result adjustment number outstanding option increase millionshare average exercise price decrease approximately addition certain stock option grant medco health employee convert medco health option term amount maintain option holder position merck co inc annual report connection merck acquisition rosetta stock option outstanding acquisition date convert option purchase share company common stock equivalent value summarize information relative company stock option plan share thousand follow number average share price outstanding december grant exercise forfeited equivalent option assume outstanding december grant exercise forfeit outstanding december grant exercise forfeit converted medco health spinoff adjustment outstanding december weight average exercise price include million option convert medco health option number share average price option exercisable december million share million share million share respectively december million share million share respectively available future grant term plan summarize information stock option outstanding exercisable december share thousand follow outstanding exercisable exercise price number average average number average range share life price share price weight average contractual life remain year weight average exercise price pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary pension benefit united states base formula consider final average pay year credit service addition company provide medical dental life insurance benefit principally eligible retiree similar benefit dependent postretirement benefit plan company use december measurement date pension postretirement benefit plan effect medicare prescription drug improvement modernization act act recognize net cost benefit obligation relate disclosure postretirement benefit plan specific authoritative guidance account federal subsidy act pende guidance issue require company change previously report informationin company change participant contribution service recognize eligibility postretirement benefit plan amendment reduce benefit obligation million generate curtailment gain million million respectively addition company record settlement loss million pension plan curtailment loss million postretirement benefit plan result reduction employment level primarily connection restructuring activity company record termination charge million pension plan million postretirement benefit plan relate expand eligibility certain employee exit restructure action note net cost company pension plan consist follow component year end december service cost interest cost expect return plan asset net amortization settlement termination benefit net pension cost net pension cost attributable plan include table million million million merck co inc annual report net cost postretirement benefit pension consist follow component year end december service cost interest cost expect return plan asset net amortization curtailment termination benefit net postretirement benefit cost cost health care life insurance benefit active employee million million million summarize information change plan asset benefit obligation follow postretirement pension benefit benefit fair value plan asset january actual return plan asset company contribution benefit pay plan asset discontinue operation fair value plan asset december benefit obligation january service cost interest cost actuarial loss benefit pay plan amendment curtailment termination benefit discontinue operation benefit obligation december fair value pension plan asset include precede table billion billion pension benefit obligation plan include table billion billion reconciliation plan fund status net asset liability recognize december follow postretirement pension benefit benefit plan asset benefit obligation unrecognized net loss unrecognized plan change net asset liability recognize asset accrue current liability defer income taxis noncurrent liability accumulate comprehensive loss weight average asset allocation investment portfolio pension postretirement benefit plan december follow u equities international equity fix income investment real estate cash investment merck co inc annual report target investment portfolio allocate equities international equity fixedincome investment real estate cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest contribution pension plan postretirement benefit plan expect million million respectively contribution pension plan expect million expect benefit payment follow postretirement pension benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service december accumulate benefit obligation billion billion respectively pension plan billion billion respectively pension plan company minimum pension liability million million december respectively represent extent accumulate benefit obligation exceed plan asset certain company pension plan decrease minimum pension liability record comprehensive income loss asset primarily reflects increase fair value plan asset certain plan result favorable asset return pension plan benefit obligation excess plan asset december fair value plan asset billion billion respectively benefit obligation billion billion respectively plan accumulate benefit obligation excess plan asset december fair value plan asset million million respectively accumulate benefit obligation million billion respectively unrecognized net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption unrecognize net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amortization unrecognized net loss companys plan december expect increase net pension postretirement benefit cost approximately million annually company reassesse benefit plan assumption regular basis assumption determine plan information follow pension postretirement benefit december net cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider long term compound annualize return historical market datum actual return company plan asset apply adjustment reflect recent capital market experience reference information company develop forward look return expectation asset category weight average expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return remain unchanged pension postretirement benefit plan weight average assumption determine international pension plan information follow december net costdiscount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year rate reach ultimate trend rate percentage point change health care cost trend rate follow effect percentage point increase decrease effect total service interest cost component effect benefit obligation merck co inc annual report income expense net year end december interest income interest expense exchange gain minority interest amortization goodwill intangible net minority interest include party share exchange gain loss arise translation financial statement dollar reduce minority interest attributable effect banyu share acquisition note result low dividend variable rate prefer unit note decrease minority interest expense associate banyu increase net primarily reflect million gain sale aggrastat product right united states realize gain company investment portfolio relate favorable interest rate environment interest pay million million million taxis income reconciliation company effective tax rate statutory rate follow tax rate statutory rate apply income continue operation taxis differential arise foreign earning tax exemption puerto rico operation state taxis domestic company contribute approximately consolidated income continue operation taxis tax income continue operation consist year end december current provision federal foreign state defer provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation advance payment equity investment pension opeb compensation relate subtotal valuation allowance total defer taxis net defer tax liability recognize prepay expense taxis asset income taxis payable deferred income taxis noncurrent liability reduction net defer tax liability primarily attributable spinoff medco health income taxis pay billion billion billion respectively stock option exercise reduce income taxis pay million million million respectively december foreign earning billion domestic earning million retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability earning include income manufacturing operation ireland taxexempt tax addition company subsidiary operate puerto rico singapore tax incentive grant expire respectively company federal income tax return audit merck co inc annual report earning share weight average common share computation basic earning common share earning common share assume dilution share million follow year end december average common share outstanding common share issuable average common share outstanding assume dilution issuable primarily stock option plan comprehensive income adoption fas january company record favorable cumulative effect accounting change million comprehensive income loss represent mark fair value purchase local currency option mature hedge anticipate foreign currency denominate sale period december million defer loss associate option mature month hedge anticipate foreign currency denominate sale period component comprehensive income loss follow pretax tax tax year end december net unrealized loss derivative net loss realization derivative net unrealized gain investment net income realization investment minimum pension liability year end december net unrealized loss derivative net income realization derivative net unrealized gain investment net income realization investment minimum pension liability year end december cumulative effect accounting change net unrealized gain derivative net income realization derivative net unrealized gain investment net income realization investment minimum pension liability net applicable minority interest component accumulate comprehensive income loss follow december net unrealized loss derivative net unrealized gain investment minimum pension liability segment reporting company operation principally manage product basis merck pharmaceutical segment include product market directly joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization institution include nonreportable human animal health segment revenue profit segment follow merck pharm aceutical total year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization merck co inc annual report segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker company allocate vast majority indirect production cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit reconciliation total segment revenue consolidate sale follow year end december segment revenue revenue revenue primarily comprise miscellaneous corporate revenue sale relate divested product business supply sale consolidated revenue geographic area derive follow year end december united states europe middle east africa japan reconciliation total segment profit consolidate income continue operation taxis follow year end december segment profit profit adjustment unallocate interest income interest expense equity income loss affiliate depreciation amortization acquire research research development expense net profit primarily comprise miscellaneous corporate profit operating profit relate divested product business supply sale adjustment represent elimination effect double count certain item income expense equity income loss affiliate include taxis pay joint venture level portion equity income report segment profit expense net include expense corporate manufacturing cost center miscellaneous income expense net property plant equipment net geographic area locate follow december united states europe middle east africa japan company disaggregate asset product service basis internal management report information notpresente merck co inc annual report management report primary responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization establish internal control management weigh cost system benefit believe system provide staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice company periodically conduct management stewardship program key management financial personnel program reinforce importance understand internal control review key corporate policy procedure system addition ethical business practice program implement reinforce company longstanding commitment high ethical standard conduct business independent auditor audit company consolidated financial statement describe report audits design purpose form opinion internal control accompany report base audit conduct accordance auditing standard generally accept united states america include consideration company internal control establish basis determine nature timing extent audit test perform recommendation internal auditor independent auditor review management control procedure implement revise appropriate respond recommendation material control weakness bring attention management management opinion year end december internal control system strong accomplished objective discuss financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include company file raymond v gilmartin judy c lewent chairman president executive vice president chief executive officer chief financial officer president human health asia report independent auditor stockholder board directors merck co inc opinion accompany consolidated balance sheet relate consolidated statement income retain earning comprehensive income cash flow present fairly material respect financial position merck co inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion discuss note financial statement company adopt statement financial accounting standard goodwill intangible asset effective january florham park new jersey pricewaterhousecoopers llp february merck co inc annual report audit committee report audit committee comprise independent director meet independent auditor management internal auditor assure carry respective responsibility audit committee discuss receive letter independent auditor confirm independence independent auditor internal auditor access committee include regular meeting management present audit committee meet independent auditor discuss fee scope result audit work include adequacy internal control quality financial reporting committee discuss independent auditor judgment quality acceptability company accounting principle clarity disclosure degree aggressiveness conservatism accounting principle underlie estimate audit committee review discuss audit financial statement management recommend board director financial statement include company file security exchange commission heidi g miller thomas e shenk chairperson samuel thi wendell p week peter c wendell compensation benefit committee report compensation benefit committee comprise independent director approve compensation objective policy employee set compensation company executive officer committee seeks ensure reward closely link company division team individual performance committee seek ensure compensation benefit set level enable merck attract retain highly qualified employee committee view stock ownership vehicle align interest employee company stockholder consistent longterm focus inherent company rdbase pharmaceutical business policy committee high proportion executive officer compensation dependent longterm performance enhance stockholder value lawrence bossidy william g bowen chairperson johnnetta b cole william daley william n kelley merck co inc annual report select financial datum merck co inc subsidiarie million share amount result year sale material production cost market administrative expense research development expense acquire research equity income affiliate gain sale business income expense net income continue operation taxis tax income income continue operation income discontinue operation net taxis net income basic earning common share continue operation discontinue operation net income earning common share assume dilution continue operation discontinue operation net income cash dividend declare cash dividend pay common share capital expenditure depreciation yearend position work capital property plant equipment net total asset longterm debt stockholder equity financial ratio income continue operation sale net income average total asset yearend statistic average common share outstanding million average common share outstanding assume dilution million number stockholder record number employee certain prior year amount restate reflect result medco health discontinue operation amount include impact implementation new distribution program wholesaler restructure cost relate position elimination add result round decrease primarily reflect impact spinoff medco health merck co inc annual report table contentstable content exhibit dear merck colleague think moment contribution company society past century think life save lengthen significantly improve result effort think family enjoy additional year brother sister parent child product service reflect lifesave lifeenhance role company play world feel enormous sense pride great sense responsibility ensure organization preserve future generation try forget medicine people profit profit follow remember fail appear george w merck word write year ago vastly different world value embody continue guide company day world technical advancement supersede marketing strategy change manufacturing process pass obsolescence value standard endure speak different language represent culture united drive good deliver breakthrough medicine integrity honesty share value merck basis success further companys value standard great effect future success company value george merck impart live continue guide action decision future generation booklet design assist make george merck vision continue reality discuss standard reflect value guide daytoday decisionmake great deal effort merck employee world go creation ask read entire booklet adhere standard model value conduct merck business think find value standard invaluable resource sincerely ray gilmartin chairman president ceotable content introduction resource relationship customer product service quality honest communication clinical trial postmarkete clinical trial gift entertainment invitation conferencessymposia fair competition gather competitive information relationship fellow employee work environment fair treatment health safety workplace harassment sexual harassment relationship shareholder conflict interest use corporate asset personal use communication tool protection company information accuracy booksrecord insider trading relationship supplier selection supplier treatment supplier relationship community society corporate responsibility public communication environmental stewardship improper payment use selection agent compliance law rule regulation boycotts importexport regulations index deferral program amend restate deferred payment director compensation plan offer letter computation ratio earning fix charge page annual report stockholders code conduct list subsidiary power attorney certify resolution board directors certification ceo certification cfo certification ceo certification cfotable content table content introduction resource relationship customer product service quality honest communication clinical trial postmarkete clinical trial gift entertainment invitation conferencessymposia fair competition gather competitive information relationship fellow employee work environment fair treatment health safety workplace harassment sexual harassment relationship shareholder conflict interest use corporate asset personal use communication tool protection company information accuracy booksrecord insider trading relationship supplier selection supplier treatment supplier relationship community society corporate responsibility public communication environmental stewardship improper payment use selection agent compliance law regulation boycotts importexport regulation political activity appendix merck leadership principle index cp corporate policy symbol code conduct indicate relevant corporate policy number policy reference provide convenience code corporate policy view intranet httphumresmerckcompolprocmainhtmtable content purpose merck value standard form basis success inspire trust confidence medical community government official regulatory agency financial market customer patient essential success important value inspire trust confidence merck employeescreate sense pride desire achieve great thing merck yes care lot result achieve care achieve comment george w merck medicine people embody value aspiration clear mean daytoday activity decisionmake member merck community booklet aim illustrate value apply standard conduct key stakeholder customer employee shareholder supplier community applicability code conduct relevant corporate policy apply conduct business behalf merck include employee executive officer eg chief executive officer chief financial officer controller etc member board director agent consultant contract labor handle merck matter exceptional situation warrant waiver company standard waiver executive officer member board director grant board director board committee waiver promptly disclose shareholder accountability responsible adhering value standard set forth code raise question uncertain standard meet violation code result variety corrective action case result disciplinary action include termination employment availability believe stakeholder entitle know business practice value standard booklet available public access website wwwmerckcom question concern refer resource list website table content customer business preserve improve human life animal health action measure success achieve goal value ability serve patient benefit appropriate use product service dedicate provide high level professional excellence health delivery system strive identify critical need health care professional consumer devote resource meeting need supplier believe develop mutually beneficial relationship supplier recognize important partner success treat honesty fairness respect community society good corporate citizen mean comply applicable law rule regulation serve society local community operate plant national international level support program advance knowledge education improve health care addition priority support program protect environment promote art cultural activity foster civic institution fellow employee ability succeed depend integrity knowledge imagination skill diversity flexibility teamwork merck employee end strive create environment mutual respect encouragement teamworka working environment reward commitment performance seek responsive need employee seek provide workplace atmosphere attract highly talented people help achieve potential responsible create climate trust respect promote productive work environment responsibility embody leadership principle know develop know develop business know support develop people communicate shareholder recognize ability meet goal depends maintain financial performance encourage investment leadingedge research development turn enable deliver effective product innovative service strive provide honest accurate timely information toour shareholder performance clear disclosure public report communication table content guideline matter detail possibly anticipate challenge face job additional resource use question business conduct booklet serve guide standard include frequently ask question intend exhaustive description company policy standard booklet find shade box contain response real question merck employee raise supplementary information number issue find refer relevant corporate policy find reference guideline policy access intranet contact human resource department question fully address resource step discuss question manager resource availableinclude specialist legal finance corporate audit human resource department office ethic adviceline information contact resource resource list website use resource need clarification policy assistance deal gray area concern possible violation standard law regulation topic not apply concerned booklet companywide global document section topic relevant certain function department helpful aware business conduct different area company decision test decision test set criterion use help determine appropriate course action simply ask action legal comply letter standard policy comply spirit standard policy look newspaper appear improper feel embarrassedif unsure contact manager resource list website guidance need value standard booklet good reputation integrity honest business practice merck enjoy good reputation value standard long source pride employee recognize operate dynamic rapidly change business environment easily lose good continually reinforce value standard employee ensure integrity remain continue priority merck employee understand company expectation suggestion employee decide compile company basic guideline business practice booklet use reference tool new corporate governance initiative mandate company code ethic emphasize need booklet question concern refer resource list website table content product service quality cp quality mean consistently satisfy customer requirement expectation deliver product service high value timely manner customer include patient health care professional health care organization government agency wholesaler distributor quality improvement area business product research laboratory patient use product service imperative provide innovative product service improve quality life achievement quality goal objective depend ability listen respect customer need business activity schedule great deal pressure modify manufacture step speed production strive streamline manufacturing process efficient possible proper channel receive approval new technique step require government regulatory agency require meet quality standard possible step unnecessary serve critical quality function questionsor suggestion process improvedconsult manager head quality operation site take action honest communication cp life depend quality product service quality information provide medical community general public information furnish customer product service include availability delivery useful accurate support scientific evidence relevant present honestly fairly proper mean mean promotional communication include description use dosage recommendation include require law regulation summary effect precaution warning contraindication effectiveness describe indicate use communicate publicly intent promote product use product approve use restrict proper exchange scientific information concern product include dissemination research finding scientific communication medium sale representative know m suppose encourage promote use product inconsistent product label physician start ask question use refer study doctor prescribe use generally speak merck sale representative provide directly physician information inconsistent contain product label advise physician merck recommend use product purpose specify product label physician desire additional information topic refer request medical services department department authorize certain limited circumstance provide information directly physician table content clinical trial clinical trial determine safety efficacy product people volunteer participate study crucial conduct trial utmost regard health safety participant further interest science society detailed standard guideline available concern clinical trial product protocol postmarkete clinical trial postmarkete clinical trial help learn safety efficacy product provide important information practice physician thirdparty payer key decisionmaker foster appropriate use merck product assist gain wide awareness acceptance product special population unique geographic location physician advise competitor provide payment prescription write product acceptable acceptable practice happen doctor participate bona fide post marketing clinical study case appropriate compensate physician additional workload participate study unrelated prescription physician write gift entertainment cp cp give gift physician customer wish safeguard public confidence physician decision solely basis patient health provide gift incentive substantial value physician customer build relationship provide occasional gift long gift primarily entail benefit patient substantial value gift include medical textbook item serve genuine educational function additionally promotional item nominal value permissible eg pen notepad calendar etc provide related physician practice localregional lawyer provide detailed definition nominal value relevant specific location invite wedding important customer culture expect guest bring cash gift wedding case cash gift prohibit consult manager believe exception company policy warrant prior write approval area divisional vice president obtain chief cardiologist major hospital request donation equipment hospital new cardiaccare unit donation violation business standardsit appropriate desirable company contribution improve quality local health care facility question consider regard following donation conflict local law ultimate beneficiary donation physician hospital hospital consider add merck product formulary donation affect perceive affect decisionmake process consult manager explore donation region table content customer addition physician build relationship important customer include health care professional wholesaler distributor respect customer promotional item nominal value permissible eg pen notepad calendar etc recognize certain culture occasion giftgive substantial nature customary expect decision situation carefully weigh prior write approval obtain area divisional vice president receive gift receipt gift common context supplier relationship guideline include ease reference convenience building relationship receive occasional gift provide gift nominal value eg pen notepad calendar etc legal gift intend likely perceive improperly influence business decision occasionally time refuse gift impractical embarrassing rare instance gift substantial value accept gift behalf company report manager turn gift localregional finance director handle disposition government official employee gift meal entertainment benefit generally provide gift meal entertainment benefit government official employee acceptable company wish avoid appearance impropriety additionally law concern appropriate gift entertainment respect group complex vary country countryand country eg local versus national official consult legal department provide gift invitation kind government employee longtime supplier send flower commemorate tenyear anniversary company return flower supplier return flower impractical embarrass supplier accept flower return supplier feel uncomfortable keeping supplier offer gift regular basis politely advise merck gift policy provide accept meal entertainment mean building relationship provide accept occasional meal social entertainment provide course bona fide business relationship accompaniment educational business discussionfunction legal consistent industry practice likely perceive attempt improperly influence business decision embarrass company receive public scrutiny customary country customer restaurant discuss business drink acceptable policy acceptable practice ensure entertainment reasonable good taste appropriate country table content potential supplier invite attend professional sporting event attend sporting event appropriate excessive supplier attend available discuss business acceptable attend important accept invitation intend likely perceive attempt improperly influence business decision example occasional unsolicited ticket regularseason sport event acceptable playoff quarterfinal semifinal require scrutiny ticket final championship event eg world cup olympics wimbledon consider excessive localregional lawyer provide detailed explanation inappropriate excessive relevant specific location invitation conferencessymposia cp cp commit conduct participate educational program share medical scientific information recognize importance ensure activity undertake appropriate professional manner ultimate goal improve patient care standard necessarily account local legal requirement restrictive local law exist precedence primary focus scientificeducational meeting agenda appropriate participant scientific agenda dominate social activity location select basis participant travel convenience cost appropriateness type meeting audience fund travel spouse companion attendee exception policy require prior write approval area divisional vice president funding travel expense important opinion leader speak mercksponsore conference like bring spouse expense permit spouse companion travel conference provide company expense mean travel lodge meal cost associate spouse presence bear company spouse companion permit attend session meeting official business discuss invite sponsor conference honor physician request issue economyclass ticket place businessclass ticket attend conference invitation extended physician company cover expense directly associate invitee attendance pay physician involve approval process new drug attend meeting ultimately pay regulatory agency approve drugsthe law regulation govern activity complex vary depend variety factor include physician government employee physician decisionmaker regulatory approval process merck product registration pende complexity legal department consult advance generally answer individual attendance great public good situation permit expense handle appropriate legal manner table content fair competition cp believe customer society benefit fair free open market compete merit product service agreement competitor fix price restrain trade principle fair competition require share exchange price bid information competitor include pricing policy discount promotion royalty warranty term condition sale competitor volunteer information trade association meeting physicians waiting room terminate conversation immediately bring situation attention legal department exchange intend innocently create appearance pricefixe bidrigging compete aggressively market customer agreementsor general understandingswith competitor concern customer distributor territory demand supplier business order retain merck business mischaracterize distort product service competitor standard fair competition matter law virtually country operate additional legal requirement comply manager ensure employee involve marketing sale purchase aware letter spirit standard applicable competition law attend trade association meet member discuss pricing strategy issue pricing strategy discuss competitor possibility pricefixe collusion occur perceive occur country prohibit discussion pricing competitor reason find situation excuse meeting immediately promptly advise legal department observe gather competitive information compete fairly honestly gather market information misrepresentation theft invasion privacy coercion additional rule informationgathering apply government bid contact manager legal department information hire employee competitor information allow volunteer employer allow employee volunteer ask nonpublic information employer ask comfortable merck employee share information competitor additionally legal implication relate disclosure confidential information company clarification consult manager legal department question concern refer resource list websitetable content work environment cp seek provide work environment attract retain highly talented people help achieve potential responsible create climate trust respect promote productive work environment responsibility describe leadership principle serve foundation human resource policy practice process leadership principle spell specific behavior expect additionally respect privacy dignity fellow employee safeguard confidentiality employee record encourage open communication receptive idea concern offer receive feedback constructively fair treatment cp meet longterm growth efficiency requirement build organization respond quickly change people achieve potential difference background experience perspective talent fundamental strength global company treat individual fairly recruit select train pay base merit experience workrelate criterion information contact human resource representative corporate human resource diversity department acceptable stipulate gender age open position business justification advertising position base gender age treat people fairly hire base solely job relate criterion right thing smart business health safety cp conduct operation high regard safety health employee protection general public responsible comply safety rule regulation take necessary precaution protect colleague report accident action correct unsafe practice condition goal continuously improve performance central safety industrial hygiene answer specific question merck safety standard necessary report minor accident not want jeopardize plant safety record maintain safety performance excellence strive accidentfree environment report accident matter minor work eliminate unsafe practice condition report minor accident important help identify hazards corrective action injury occur uncover unsafe condition shutdown operationsin circumstance believe imminent danger condition exist delay jeopardize safety authorize shutdown operation shutdown operation extremely disruptive response safety problem require order protect people facility hazard merck expect employee discover unsafe condition report supervisor condition remedie effective manner table content drug alcohol abuse use illegal drug alcohol abuse create health safety risk workplace possession sale use illegal drug company time property companysponsore event prohibit similarly impairment alcohol conduct merck business companysponsore event prohibit important case drug alcohol abuse bring management attention immediately information resource location deal substance abuse resource list website workplace harassment cp strive maintain environment free harassment employee respect workplace harassment define action create intimidate hostile offensive work environment example include limited disparage comment base race gender religion nationality sexual harassment sexual harassment form workplace harassment sexual nature affect dignity man woman work sexual harassment include limited demand sexual consideration exchange job benefit threaten take adverse employment action sexual favor grant unwelcome physical contact feel harassed inform offender action unwelcome comfortable direct approach fail correct problem discuss matter supervisor human resource refer resource list website permissible date subordinate consensual relationship unacceptable romantic relationship direct indirect reporting relationship relationship inevitably damage morale disrupt productivity workplace inherent conflict interest manage romantic relationship act impartially relationship likely perceive negatively immediately disclose relationship manager human resource date colleague acceptable yes provide direct indirect reporting relationship common country joke certain nationality acceptable jest officehumor important element life inside outside office acceptable fun expense base national ethnic difference offensive behavior intend contribute environment intolerance sure joke comment appropriate refrain communicating question concern refer resource list website table content conflict interest cp responsibility shareholder decision strictly basis merck good interest regard personal concern potential conflict interest arise involve directly indirectly outside activity impair perceive impair business judgment example actual potential conflict interest include personal financial interest customer distributor competitor supplier close family member eg spouse child sible parent inlaw work customer distributor competitor supplier receive form compensation customer distributor competitor supplier personal interest potential gain company transaction key addressing conflict interest disclosure disclose potential conflict company action require believe potential conflict interest discuss situation manager certain employee include director officer executive designate employee file annual conflict interest certification describe actual potential conflict interest company loan employee particularly sensitive subject specific scrutiny company loan executive officer member board director prohibit existence july husband work competitor need inform company potential conflict interest disclose manager potential conflict disclose company step properly address situation necessary example work product compete product work merck company elect assign product fianc work distributor family member associated merck business disclose manager close relationship fianc consider potential conflict interest determine true case discuss matter manageri share stock british telecom bt provide phone service merck report conflict interest investment represent percent outstanding share publicly own company british telecom investment constitute percent value investment consider potential conflict interest policy table content use corporate asset cp shareholder right expect company asset properly maintain economical efficient manner general rule use company equipment resource exclude communication tool personal use time personal use corporate resource acceptable question situation discuss manager support company work advanced chemistry degree use company laboratory equipment weekend study health safety risk personal use company laboratory equipment permit believe extraordinary circumstance warrant exception discuss situation manager personal use communication tool company encourage efficient effective use communication tool email intranet internet voicemail telephone photocopier fax machine accomplish business objective tool allow efficiently accomplish personal activity use generally permit provide adverse effect productivity work environment usage conform exist standard policy communication tool general guideline communication tool include telephone use common sense good judgment company telephone personal business quick home acceptable lengthy overseas call acceptable fax photocopier personal use acceptable provide infrequent insubstantial photocopy tax return acceptable copying announcement sport club acceptable internet email personal use interfere work productivity exceed nominal cost company use common sense good judgment internet shopping lunch hour acceptable spending afternoon surfing web acceptable particular division location adopt restrictive guideline concern personal use communication tool case restrictive standard apply case personal use communication tool subject discretion manager process buying house immediately fax document agent use company fax leave office find public fax use good judgment case use company fax personal use company fax machine acceptable provide usage insubstantial infrequent question situation discuss manageri go holiday thailand family acceptable use internet check local weather yes employee use internet email system personal activity interfere productivity work environment note follow example inappropriate use internet email system strictly forbid time table content download transmit pornographic sexist racially ethnically insensitive material post opinion views regard company company business internet newsgroup chat room bulletin board etc specifically authorize company conduct private business activity internet email system information contact corporate computer resource department protection company cp information cp information important company asset protect loss confidential information extremely damaging competitive position example confidential information include limited pricing formulation research result manufacturing method financial datum marketing sale strategy plan disclose confidential company information valid business purpose proper authorization management responsible protect confidentiality company information general guideline protect confidential company information include discuss sensitive company business public password protection computer file secure sensitive information lock file cabinet secure sensitive information laptop computer travel exercise caution speakerphone cellular phone leave employment merck obligated maintain confidentiality merck information return document file include electronicallystore information overheard merck employee discuss company business airplane believe information discuss sensitive confidential advise party overheard merck employee responsibility ensure confidential proprietary information disclose public home computer come chat room sensitive merck information divulge disclosure confidential company information strictly forbid seriously harm company try achieve business objective discuss observation manager adviceline contact office ethic advise observation question concern refer resource list website table content accuracy booksrecord cp decision base information record level company incomplete inaccurate information lead poor decision negative consequence example improper recording revenue expense lead misrepresentation company financial position illegal incomplete inaccurate manufacturing document jeopardize supply product violate regulation accuracy public disclosure certain disclosure company periodic report document file governmental agency public communication company fair accurate timely understandable obligation apply employee include financial executive responsibility preparation report include draft reviewing signing certify information contain require operate environment open communication compromise proprietary confidentiality concern concern aspect financial disclosure discuss concern manager finance organization legal department office ethic adviceline employee contact employee raise question concern questionable accounting auditing matter immediately report concern office ethic record information honestly accurately include limited expense revenue research test result production quality datum corporate information financial transaction payment authorized record strict compliance corporate accounting method require cooperation internal external auditor contact divisional controller corporate audit group client director question concern proper record financial transaction december money leave annual budget acceptable prepay year activity year budget activity payment match period event occur year payment record take place year activity set year payment charge year budget account table content sale order came confirm day book close acceptable include unconfirmed sale early period sale officially take place confirm good ship misrepresentation include unconfirmed sale early period delay process sale order period help attain income target period sale order receive process accordance standard operating procedure transaction inappropriate manipulate sale order process financial period insider trading cp merck strive preserve fair open market buy selling company security buy sell merck security basis nonpublic material information material inside information information reasonable investor consider important make investment decision example include knowledge acquisition divestiture new product process financial information corporate earning restriction apply nonpublic material information company learn capacity merck employee prohibit disclose nonpublic material information inside outside merck legitimate business reason proper management authorization inside information refrain trading affect security begin second trading day public disclosure information doubt purchase sale security violate insider trading standard consult legal department question concern refer resource list website table content selection supplier cp select good service well contribute longterm merck choose supplier base price quality delivery service diversity reputation factor include environmental business practice take consideration merck condemn use force labor exploitative child labor expect supplier respect principle suspect supplier child labor discuss observation manager contact adviceline prefer send note office ethic advise observation treatment supplier treat supplier subcontractor fairness integrity respect term condition agreement supplier honor commitment strive pay time careful protect confidential proprietary information supplier ensure supplier give opportunity compete business obtain competitive bid feasible acceptable copy company software home computer company business generally acceptable respect term softwarelicense agreement limit number machine software instal determine acceptable particular software consult corporate computer resource departmenttable content corporate responsibility cp merck believe essential component corporate responsibility provide support charitable philanthropic organization benefit society local plant community international level merck make cash contribution directly merck company foundation donate product inkind service qualified organization program address need society support merck overall business mission enhance health philanthropic outreach merck guide strategic priority worldwide advance scientific knowledge education improve health care merck support initiative address select health care issue fund donate mectizan treat river blindness merck medicine address health care need develop country addition priority funding provide support program protect environment promote art cultural activity foster civic institution appropriate merck provide assistance response major disaster medical emergency information contact corporate office contribution whitehouse station merck company foundation merck company foundation usbase private charitable foundation establish merck foundation fund entirely company merck chief source funding support qualified nonprofit charitable organization mission foundation advance biomedical science training education improve health care worldwide support program art civic environment inception million contribute foundation educational health social service civic cultural environmental charitable organization public communication cp communication news medium potentially important reflect company image business vital communication company consistent regulatory legal obligation fulfil communication accurate responsible keeping merck medical legal policy medium public request information refer coordinated public affair presentation conference press coverage likely respond m approach medium follow presentation journalist approach scientist executive presentation professional forum press coverage likely result public affair advise advance question answer prepare feel free clarify reporter formally present meeting question formally present refer public affair copy slide give prior clearance merck research laboratory public affair jeopardize scientific publication processif question concern refer resource list website table content environmental stewardship cp responsibility protect environment high priority comply letter spirit environmental law regulation respect environment country operate provide consumer information help handle product environmentally responsible way central safety environment answer specific question merck environmental standard check safety environment web site mmdmerckcomse availability new manual environmental standard law country prohibit dump waste onsite dispose merck waste way disposal method accordance merck environmental standard specific practice vary depend type waste merck develop good practice global environmental standard facility case standard require action exceed law individual country allow site service manager responsibility buying replacement light bulb equipment merck goal continuous improvement mean select environmentallybeneficial option necessarily cost environmentallybeneficial option disproportionate benefit obtain generally cost differential option significant real environmental benefit result environmentally beneficial option select environmental commitment provide inherent protection way design operate facility process ensure trust community promote resource conservation waste minimization minimization release chemical environment provide employee customer supplier public authority communitie appropriate information inform decisionmaking continuously improve table content improper payment cp promote good government fair impartial administration law promise offer payment money value government official political party intent induce favorable business treatment improperly affect government decision standard necessarily account local legal requirement restrictive local law exist precedence general consider ordinary reasonable business entertainment gift insubstantial value customary legal local market improper seek advice legal department uncertainty propriety legality action additional information refer gift entertainment policy tell pay gratuity minor official clear product custom company provide gratuity official ensure execution official duty seek advice manager legal department use selection agent engage reputable qualified individual firm consultant agent representative distributor compensation arrangement reasonable relation service perform integrity performance merck standard employee agent alike business ignorance standard acceptable excuse improper behavior acceptable improper behavior rationalize company good interest act impropriety advance interest company company ensure agent comply merck standard responsibility employee make recommendation conduct research ensure agent reputable minimum include research party multinational company agent work past information reflect approval memorandum submit management compliance law rule regulation cp good corporate citizen mean comply applicable law rule regulation manager responsible communicate relevant rule regulation employee assistance contact legal department boycotts usbased company merck operation include foreign subsidiary comply law pertain foreign boycotts law primarily refer arab boycott israel time time boycott issue arise variety activity prohibit antiboycott law include furnish information merck person past present prospective relationship boycott country blacklist company pay honor confirm letter credit contain boycott provisionsif question concern refer resource list website table content law require certain request boycott information report government antiboycott legislation complex request direct immediately legal department importexport regulation export sell drug proper approval merck research laboratory clinical regulatory development review committee addition drug meet legal requirement produce country country drug export import export country embargo eg sudan iran libya cuba import export certain individual organization contact prohibit government agency justify send medicine people need live place political favor united states return right operate united states obligate comply applicable united states law apply operationswhether agree law note law pertain export control apply merck operation outside country operate illegal comply trade embargo regulation certain country handle situation transnational compliance embargo regulation complex issue vary country country concern direct legal department political activity good corporate citizenship require unfairly illegally influence political process community operate complexity diversity law regulation govern corporate political activity political contribution relate activity undertake prior approval chief executive officer private citizen participate political process include contribute candidate party choice use company time property resource personal political activity table content table content table content index accident safety alcohol book record boycotts clinical trial protocol competitor competitive information fair competition computer software confidential information confidentiality commitment employee conflict interest corporate asset use date coworker discrimination fair treatment drug illegal email internet employment equal relative entertainment accept offering gift environment work fair treatment fraternization gift conferencessymposia give receive meal entertainment ticket harassment insider trading internet invitation gift kickback medium office equipment personal use political activity quality product service regulation importexport relationship communities society family personal fellow employee shareholder supplier romantic relationship safety sexual harassment shareholder socialize coworker fraternization stock company supplier relationship supplier ticket gift exhibit merck co inc subsidiary follow list subsidiary company business state country state incorporation abello farmacia sl spain algonquin sarl luxembourg amrad pharmaceuticals pty ltd australia aventis pasteur msd denmark aventis pasteur msd gestion sa france aventis pasteur msd gmbh austria aventis pasteur msd gmbh germany aventis pasteur msd ltd great britain aventis pasteur msd ltd ireland aventis pasteur msd nvsa belgium aventis pasteur msd sa spain aventis pasteur msd spa italy aventis pasteur msd snc france banyu pharmaceutical company ltd japan banyuasc co ltd japan blue jay investments cv netherlands brc ltd bermuda british united turkeys limited great britain centra medicamenta otc spa italy charles e frosst new zealand ltd new zealand charles e frosst uk limit great britain chibret denmark chibret pharmazeutische gmbh germany chippewa holdings llc delaware cloverleaf international holding sa luxembourg cm delaware llc delaware comsort inc delaware coordinate patient care scandinavia norway crosswind bv netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holding sa panama frosst iberica sa spain frosst laboratories inc delaware frosst portuguesa produto farmaceuticos lda portugal hangzhou msd pharmaceutical company limit chinacountry state incorporation hawk falcon llc delaware hubbard isa llc delaware hubbard isa sas france infodoc norway infodoc international norway international indemnity ltd bermuda istituto di richerche di biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceutical company new jersey johnson johnsonmsd consumer pharmaceutical limit great britain kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto oy viistotie finland laboratoire martinjohnson johnsonmsd sas france laboratoire merck sharp dohmechibret snc france laboratorios abello sa spain laboratorios biopat sa spain laboratorios chibret sa spain laboratorios frosst sa spain laboratorios neurogard sa spain laboratorios quimicofarmaceutico chibret lda portugal maple leaf holding srl barbados mcm vaccine co pennsylvania medco de mexico manage care de rl de cv mexico medco holdings de rl de cv mexico medco manage care sl spain medco servicios de mexico de rl de cv mexico merck company incorporate delaware merck borinquen holdings inc delaware merck capital resources inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck enterprises canada ltd canada merck finance co inc delaware merck foreign sales corporation ltd bermuda merck frosst canada co canada merck frosst canada ltd canada merck hamilton inc california merck holdings ii corp delaware merck holdings inc delaware merck institute vaccinology delaware merck investment co inc delaware merck liability management company delaware merck lmc cash management bermuda ltd bermuda merck lmc cash management inc delaware merck resource management inc delaware country state incorporation merck respiratory health company nevada merck sh inc delaware merck sharp dohme france merck sharp dohme lebanon sal lebanon merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme europe inc delaware merck sharp dohme holding limit great britain merck sharp dohme ia corp delaware merck sharp dohme international limited bermuda merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealand merck sharp dohme panama sa panama merck sharp dohme philippines inc philippines merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden ab sweden merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme bv netherlands merck sharp dohme chibret ag switzerland merck sharp dohme doo croatia merck sharp dohme de espana sa spain merck sharp dohme de mexico sa de cv mexico merck sharp dohme de venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limit great britain merck sharp dohme gmbh austria merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme idea inc switzerland merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international service bv netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland hf iceland merck sharp dohme llc russian federation merck sharp dohme limit great britain merck sharp dohme pakistan limited pakistan merck sharp dohme overseas finance nv neth antille merck sharp dohme peru srl peru merck sharp dohme quimica de puerto rico inc delaware merck sharp dohme de rl de cv mexico merck sharp dohme sa morocco merck sharp dohme tunisie sarl tunisia country state incorporation merck sharp dohme limitada portugal merck sharp dohme ilaclari limited sirketi turkey merck technology company inc nevada merck ventures inc delaware merial animal health ltd great britain merial gmbh germany merial japan ltd japan merial inc delaware merial italia spa italy merial laboratorios sa spain merial limitedllc great britaindelaware merial sas france msd japan co ltd japan msd nippon holding bv netherlands msd norge norway msd proprietary limited south africa msd thailand ltd thailand msd chibropharm gmbh germany msd finance bv netherland msd international holdings inc delaware msd ireland holdings sa luxembourg msd ireland investment ltd bermuda msd korea ltd koreadelaware msd lakemedel scandinavia aktiebolog sweden msd latin america services ltd bermuda msd magyarorszg kereskedelmi szolgltat kft hungary msd overseas manufacturing co ireland ireland msd overseas manufacturing co bermuda msd pembroke ltd bermuda msd polska sp zoo poland msd sharp dohme gmbh germany msd somerset ltd bermuda msd technology singapore pte ltd singapore msd technology lp delaware msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd warwick manufacturing ltd bermuda msdessex gmbh switzerland msdsp ltd great britain msp distribution service c llc nevada msp distribution service r llc nevada msp marketing service c llc nevada msp marketing service r llc nevada msp singapore company llc delaware msp singaporesub llc delaware msp technology company llc delaware neopharme spa italy nippon merckbanyu co ltd japan country state incorporation pasteur vaccin sa france readington holdings inc new jersey readington investments inc new jersey rosetta inpharmatics llc delaware ruskin limited bermuda sharp dohme sa spain stellarx inc nevada suomen msd oy finland telerx marketing inc pennsylvania msd foundation limit great britain thomas morson son limited great britain tradewind manufacture srl barbados transrow manufacturing ltd bermuda uab merck sharp dohme lithuania varipharm arzneimittel gmbh germany woelm pharma gmbh co arzneimittelvertrieb ohg germany woelm pharma gmbh co ohg germany woelm pharma verwaltung gmbh germany exhibit power attorney undersign appoint celia colbert kenneth c frazier severally hisher true lawful attorney attorney execute behalf undersign behalf company officer director thereof attesting seal company annual report merck co inc fiscal year end december securities exchange act include amendment thereto